[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 419
1. Zhang S, Qiu X, Gu Y, Wang E: Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer. Lung Cancer; 2008 Dec;62(3):295-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer.
  • However, the involvement of PYK2 in human non-small cell lung cancer (NSCLC) has not yet been determined.
  • In the present study, 90 patients with NSCLC (represented by adenocarcinoma and squamous cell carcinoma) were included retrospectively.
  • Patients with higher expression of PYK2 had advanced stage of NSCLCs (I+II versus III+IV, p=0.012).
  • In the cell studies, extensive expression and activation of PYK2 were both found in higher metastatic BE1 cells.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Carcinoma, Non-Small-Cell Lung / enzymology. Focal Adhesion Kinase 2 / metabolism. Lung Neoplasms / enzymology
  • [MeSH-minor] Adenocarcinoma / enzymology. Adenocarcinoma / secondary. Blotting, Western. Carcinoma, Squamous Cell / enzymology. Carcinoma, Squamous Cell / secondary. Extracellular Signal-Regulated MAP Kinases / metabolism. Gene Expression Regulation, Neoplastic. Humans. Immunoenzyme Techniques. Lung / enzymology. Lung / pathology. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Retrospective Studies. Up-Regulation


2. Omlin A, D'Addario G, Gillessen S, Cerny T, von Hessling A, Früh M: Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. Lung Cancer; 2009 Sep;65(3):383-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung.
  • A 53-year-old woman was with adenocarcinoma of the lung metastatic to the brain was treated after several lines of chemotherapy with pemetrexed.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antimetabolites, Antineoplastic / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19375814.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


3. Furák J, Troján I, Szöke T, Agócs L, Csekeö A, Kas J, Svastics E, Eller J, Tiszlavicz L: Lung cancer and its operable brain metastasis: survival rate and staging problems. Ann Thorac Surg; 2005 Jan;79(1):241-7; discussion 241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer and its operable brain metastasis: survival rate and staging problems.
  • BACKGROUND: We assessed the survival rates regarding different stages of operable lung cancers causing operable brain metastasis in patients with or without cancer-related symptoms.
  • The correlation between survival rates and the disease-free interval between lung surgery and metastasectomy was studied.
  • METHODS: Sixty-five patients were operated on for lung cancer and brain metastases.
  • The study group comprised of patients with lung cancer in the following stages: 17 patients in stage I (1 patient in stage IA, 16 patients in stage IB), 16 patients in stage II (2 patients in stage IIA, 14 patients in stage IIB), 9 patients in stage IIIA, 4 patients in stage IIIB, and 19 patients in stage IV.
  • Forty-four patients were symptom-free for lung cancer and 21 patients manifested lung cancer related symptoms.
  • RESULTS: The 5-year survival rates were as follows: stage I = 22%, stage II = 20%, stage IIIA = 22%, stage IIIB = 0%, and stage IV = 23% after lung resections.
  • The 5-year survival rate after metastasectomy was significantly greater (26% vs 5%) in patients without lung cancer related symptoms (p = 0.05).
  • CONCLUSIONS: The 5-year survival rate in stage I, II, IIIA, and IV lung cancer with operable hematogenous brain metastases corresponds to that in the customary stage IIIA (23%).
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adult. Aged. Combined Modality Therapy. Cranial Irradiation. Craniotomy. Disease-Free Survival. Female. Humans. Hungary / epidemiology. Life Tables. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Pneumonectomy. Radiotherapy, Adjuvant. Reoperation. Spinal Cord Neoplasms / secondary. Spinal Cord Neoplasms / surgery. Survival Analysis. Survival Rate


Advertisement
4. Souquet PJ, Krzakowski M, Ramlau R, Sun XS, Lopez-Vivanco G, Puozzo C, Pouget JC, Pinel MC, Rosell R: Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer. Clin Lung Cancer; 2010 Mar 1;11(2):105-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer.
  • The study was also intended to define the response rate of vinflunine in combination with cisplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) at the recommended dose.
  • PATIENTS AND METHODS: Patients were required to have a histologically confirmed diagnosis of NSCLC not amenable to curable treatment or stage IV disease.
  • CONCLUSION: These results place the vinflunine/cisplatin combination among the most active doublets in this treatment setting and warrant further development in phase III trials of first-line treatment of patients with advanced metastatic NSCLC.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Female. Humans. Injections, Intravenous. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Survival Rate. Tissue Distribution. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20199976.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5BF646324K / vinflunine; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


5. Yamamoto H, Sekine I, Yamada K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T: Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel. Oncology; 2008;75(3-4):169-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender differences in treatment outcomes among patients with non-small cell lung cancer given a combination of carboplatin and paclitaxel.
  • OBJECTIVES: It was the aim of this study to investigate gender differences in the outcomes of carboplatin and paclitaxel chemotherapy in patients with unresectable stage IIIB-IV non-small cell lung cancer (NSCLC).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Sex Factors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2008 S. Karger AG, Basel.
  • (PMID = 18827494.001).
  • [ISSN] 1423-0232
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


6. Wu YL, Yang JJ, Lin JY, Huang YJ, Liao RQ, Huang YS, Zhou Q, Xu CR, Wang Z: [Gefitinib target treatment in non-small cell lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi; 2007 Feb;30(2):98-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gefitinib target treatment in non-small cell lung cancer].
  • OBJECTIVE: To evaluate the efficacy, target population and influencing factors of Gefitinib in patients with non-small-cell lung cancer (NSCLC) pretreated with platinum.
  • Adenocarcinoma was the only predictor for therapeutic effect in the Cox model (P = 0.004).
  • CONCLUSION: Gefitinib is the drug of choice for patients with heavily pretreated stage III(B) and IV adenocarcinoma of NSCLC with safe and accepted toxicity profile.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17445469.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


7. Wang J, Kuo YF, Freeman J, Markowitz AB, Goodwin JS: Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer. Cancer; 2008 Jan 15;112(2):382-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Temporal trends and predictors of perioperative chemotherapy use in elderly patients with resected nonsmall cell lung cancer.
  • BACKGROUND: The authors assessed patterns of perioperative chemotherapy use in elderly patients with resected stage I, II, or IIIA nonsmall cell lung cancer (NSCLC) from 1992 to 2002.
  • METHODS: By using data from the Surveillance, Epidemiology, and End Results Program, 11,807 patients were identified who had resected stage I, II, or IIIA NSCLC between 1992 and 2002 and survived >or=120 days beyond diagnosis.
  • RESULTS: In total, 957 patients with stage I, II, or IIIA NSCLC (8.1% of the study population) received perioperative chemotherapy.
  • The proportion of patients receiving chemotherapy for stage I NSCLC changed little during the study period.
  • Of 3230 patients with stage II and IIIA NSCLC, 609 patients (18.9%) received chemotherapy, 423 patients (13%) received chemotherapy combined with radiation.
  • Younger age, being married, having advanced-stage tumor or adenocarcinoma, having a later diagnosis year, receiving radiation, and seeing an oncologist were predictors for the receipt of chemotherapy (P< .001).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy


8. Mori K, Kobayashi H, Kamiyama Y, Kano Y, Kodama T: A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol; 2009 Jun;64(1):73-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of weekly chemotherapy with paclitaxel plus gemcitabine as a first-line treatment in advanced non-small-cell lung cancer.
  • PURPOSE: The efficacy and toxicity of combined paclitaxel (PTX) and gemcitabine (GEM) was evaluated as a protocol for first-line chemotherapy in 40 patients with advanced non-small-cell lung cancer (NSCLC).
  • METHODS: Paclitaxel, 100 mg/m(2), was administered intravenously (IV) as a 1-h infusion, followed by GEM, 1,000 mg/m(2), IV over 30 min on days 1 and 8 of a 21-day cycle.
  • Thirteen patients (32%) had initial stage IIIB disease and 27 patients (68%) had stage IV disease.
  • Histological subtypes were adenocarcinoma (73%) and squamous cell carcinoma (25%).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18941748.001).
  • [ISSN] 1432-0843
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


9. Vischioni B, Oudejans JJ, Vos W, Rodriguez JA, Giaccone G: Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients. Mol Cancer Ther; 2006 Nov;5(11):2905-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent overexpression of aurora B kinase, a novel drug target, in non-small cell lung carcinoma patients.
  • We assessed aurora B expression in a series of 160 non-small cell lung cancer (NSCLC) samples (60% stage I, 21% stage II, 11% stage III, and 8% stage IV).
  • In addition, aurora B expression predicted shorter survival for the patients with adenocarcinoma histology, at both univariate (P = 0.020) and multivariate (P = 0.012) analysis.
  • However, expression of survivin in the nucleus was preferentially detected in stage I and II than in stage III and IV (P = 0.007) in the overall series of NSCLC samples.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Protein-Serine-Threonine Kinases / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121938.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline; 0 / BIRC5 protein, human; 0 / Benzamides; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Enzyme Inhibitors; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Quinazolines; EC 2.7.11.1 / AURKB protein, human; EC 2.7.11.1 / Aurora Kinase B; EC 2.7.11.1 / Aurora Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


10. Davies AM, Chansky K, Lara PN Jr, Gumerlock PH, Crowley J, Albain KS, Vogel SJ, Gandara DR, Southwest Oncology Group: Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339). J Thorac Oncol; 2009 Jan;4(1):87-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339).
  • INTRODUCTION: Bortezomib is a small-molecule proteasome inhibitor with single-agent activity in patients with non-small cell lung carcinoma (NSCLC) and synergy with gemcitabine in preclinical studies.
  • METHODS: Patients with selected stage IIIB/IV NSCLC, performance status 0-1, and no history of brain metastasis received up to six 21-day cycles of gemcitabine 1000 mg/m, days 1 and 8, carboplatin area under curve 5.0, day 1, and bortezomib 1.0 mg/m, days 1, 4, 8, and 11.
  • RESULTS: One-hundred-fourteen patients (52% adenocarcinoma, 85% stage IV) received a median of 3.6 treatment cycles.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adult. Aged. Boronic Acids / administration & dosage. Bortezomib. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cohort Studies. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Pyrazines / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Clin Oncol. 2001 Jul 1;19(13):3210-8 [11432888.001]
  • [Cites] J Surg Res. 2001 Sep;100(1):11-7 [11516199.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):92-8 [11784875.001]
  • [Cites] Lung Cancer. 2002 Jul;37(1):9-14 [12057861.001]
  • [Cites] Oncologist. 2002;7(3):226-33 [12065795.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2505-11 [12171876.001]
  • [Cites] J Clin Oncol. 2002 Nov 1;20(21):4285-91 [12409326.001]
  • [Cites] Clin Cancer Res. 2003 Mar;9(3):1145-54 [12631620.001]
  • [Cites] Lung Cancer. 2003 Jul;41(1):81-9 [12826316.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S89-96 [12867067.001]
  • [Cites] Lung Cancer. 2003 Sep;41(3):321-31 [12928123.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):33714-23 [12821677.001]
  • [Cites] Cancer Sci. 2004 Feb;95(2):176-80 [14965369.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):5022-6 [15297403.001]
  • [Cites] Cancer Chemother Pharmacol. 2004 Oct;54(4):343-53 [15197486.001]
  • [Cites] Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):13-20 [15339054.001]
  • [Cites] Oncology (Williston Park). 2004 Jul;18(8 Suppl 5):21-6 [15339055.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2004 Spring;16(1):28-39 [15366685.001]
  • [Cites] Ann Thorac Surg. 2004 Oct;78(4):1207-14; discussion 1207-14 [15464472.001]
  • [Cites] Nephron. 1976;16(1):31-41 [1244564.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):190-6 [15625373.001]
  • [Cites] Clin Lung Cancer. 2004 Dec;6 Suppl 2:S89-96 [15638966.001]
  • [Cites] N Engl J Med. 2005 Jun 16;352(24):2487-98 [15958804.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3777-84 [16099887.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9097-104 [16361616.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jun;58(3):177-89 [16427303.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3113-20 [16754936.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):781-92 [16847887.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5025-33 [17075122.001]
  • [Cites] Oncology (Williston Park). 2006 Nov;20(12):1515-24; discussion 1524-5, 1530, 1535 [17153906.001]
  • [Cites] N Engl J Med. 2006 Dec 14;355(24):2542-50 [17167137.001]
  • [Cites] Ann Oncol. 2007 Feb;18(2):317-23 [17079694.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):68-74 [18166843.001]
  • (PMID = 19096312.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA86780; United States / NCI NIH HHS / CA / U10 CA027057; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / N01 CA035431; United States / NCI NIH HHS / CA / U10 CA045560; United States / NCI NIH HHS / CA / U10 CA035128; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / U10 CA063850; United States / NCI NIH HHS / CA / N01 CA032102; United States / NCI NIH HHS / CA / U10 CA045808; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / N01 CA045807; United States / NCI NIH HHS / CA / U10 CA032102-32; United States / NCI NIH HHS / CA / N01 CA035119; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / U10 CA180846; United States / NCI NIH HHS / CA / N01 CA046441; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / U10 CA035281; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / N01 CA063844; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / U10 CA035178; United States / NCI NIH HHS / CA / U10 CA032102; United States / NCI NIH HHS / CA / U10 CA046282; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / N01 CA035178; United States / NCI NIH HHS / CA / N01 CA038926; United States / NCI NIH HHS / CA / U10 CA067575; United States / NCI NIH HHS / CA / N01 CA027057; United States / NCI NIH HHS / CA / U10 CA046441; United States / NCI NIH HHS / CA / U10 CA058882; United States / NCI NIH HHS / CA / U10 CA020319; United States / NCI NIH HHS / CA / U10 CA038926; United States / NCI NIH HHS / CA / U10 CA086780; United States / NCI NIH HHS / CA / U10 CA042777; United States / NCI NIH HHS / CA / U10 CA035431; United States / NCI NIH HHS / CA / U10 CA035119; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / U10 CA046368; United States / NCI NIH HHS / CA / N01 CA067575; United States / NCI NIH HHS / CA / U10 CA035090; United States / NCI NIH HHS / CA / U10 CA063844; United States / NCI NIH HHS / CA / U10 CA045807; United States / NCI NIH HHS / CA / N01 CA045560
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 0W860991D6 / Deoxycytidine; 69G8BD63PP / Bortezomib; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ NIHMS244778; NLM/ PMC3024911
  •  go-up   go-down


11. Lyons G, Quadrelli S, Chimondegy D, Iotti A, Silva C: [Bronchioalveolar carcinoma: five year survival]. Medicina (B Aires); 2006;66(4):313-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The epidemiology and prognosis of bronchioalveolar carcinoma (BAC) is different from adenocarcinoma.
  • Patients were classified as stage IA 11/24, IB 5/24 IIIB in 2/24 and IV in 6/24.
  • Five-year survival in stage IA patients was 80%.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / mortality. Lung Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma, Mucinous / mortality. Adenocarcinoma, Mucinous / pathology. Bronchoscopy. Female. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16977966.001).
  • [ISSN] 0025-7680
  • [Journal-full-title] Medicina
  • [ISO-abbreviation] Medicina (B Aires)
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Argentina
  •  go-up   go-down


12. Tang XJ, Zhou QH, Zhang SF, Liu LX: [Expressions of Nm23, E-cadherin, and beta-catenin in non-small cell lung cancer and their correlations with metastasis and prognosis]. Ai Zheng; 2005 May;24(5):616-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expressions of Nm23, E-cadherin, and beta-catenin in non-small cell lung cancer and their correlations with metastasis and prognosis].
  • This study was to investigate correlations of expressions of nm23, E-cadherin, and beta-Catenin in non-small cell lung cancer (NSCLC) to metastasis and prognosis, and their interrelations.
  • RESULTS: The expressions of nm23, E-cadherin and beta-Catenin were significantly weaker in NSCLC tissues than in adjacent non-cancerous tissues, and benign pulmonary tissues (53.0% vs. 64.8%, and 76.9%, P < 0.01; 53.1% vs. 79.7%, and 83.5%, P < 0.01; and 47.2% vs. 80.6%, and 85.6%, P < 0.01), significantly weaker in NSCLC tissues with lymph node metastasis than in those without metastasis (48.0% vs. 65.0%, P < 0.01; 47.3% vs. 60.5%, P < 0.01; and 41.8% vs. 60.3%, P < 0.01), and significantly weaker in NSCLC tissues of stage III-IV than in those of stage I-II (44.8% vs. 67.2%, P < 0.01; 46.6% vs. 64.3%, P < 0.01; 38.1% vs. 63.1%, P < 0.01).
  • [MeSH-major] Cadherins / metabolism. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Nucleoside-Diphosphate Kinase / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Bronchiectasis / metabolism. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Humans. Lung / metabolism. Lymphatic Metastasis. Male. Middle Aged. NM23 Nucleoside Diphosphate Kinases. Neoplasm Staging. Prognosis. Survival Rate


13. Papadaki C, Mavroudis D, Trypaki M, Koutsopoulos A, Stathopoulos E, Hatzidaki D, Tsakalaki E, Georgoulias V, Souglakos J: Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen. Clin Cancer Res; 2009 Jun 1;15(11):3827-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumoral expression of TXR1 and TSP1 predicts overall survival of patients with lung adenocarcinoma treated with first-line docetaxel-gemcitabine regimen.
  • The prognostic and predictive value of tumoral expression of both genes was evaluated in patients with lung adenocarcinoma treated with first-line docetaxel and gemcitabine.
  • EXPERIMENTAL DESIGN: Tumor samples from 96 patients, with stage IIIB (with pleural effusion) or IV lung adenocarcinomas, were analyzed for TXR1 and TSP1 mRNA levels by quantitative real-time PCR, from microdissected cells derived from patients' primary tumors.
  • CONCLUSION: These data confirm the in vitro model of TSP1 and TXR1 effect on taxane resistance in lung adenocarcinomas and merit further evaluation.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Basic Helix-Loop-Helix Leucine Zipper Transcription Factors / genetics. Lung Neoplasms / drug therapy. Repressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19435835.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; 0 / PRR13 protein, human; 0 / RNA, Messenger; 0 / Repressor Proteins; 0 / SPZ1 protein, human; 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


14. Nogami N, Kuyama S, Harita S, Miyata A, Kikuchi T, Kaneyoshi A, Norimune S: [A case of elderly non-small-cell lung cancer (NSCLC) treated in cooperation with a local hospital and with vinorelbine monotherapy]. Gan To Kagaku Ryoho; 2005 Feb;32(2):261-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of elderly non-small-cell lung cancer (NSCLC) treated in cooperation with a local hospital and with vinorelbine monotherapy].
  • A 79-year-old man was referred to our hospital for evaluation of a nodular shadow in his right lung.
  • Neck lymph node biopsy yielded a diagnosis of adenocarcinoma.
  • The clinical stage was IV, and he underwent chemotherapy of vinorelbine 25 mg/m2 on days 1 and 8.
  • The patient could receive long-term continuation of the chemotherapy medication, and showed improvement in terms of prolongation of life and QOL.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Cooperative Behavior. Lung Neoplasms / drug therapy. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15751646.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  •  go-up   go-down


15. Su YC, Hsu YC, Chai CY: Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma. Kaohsiung J Med Sci; 2006 Jan;22(1):14-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of TTF-1, CK20, and CK7 immunohistochemistry for diagnosis of primary and secondary lung adenocarcinoma.
  • Thyroid transcription factor-1 (TTF-1), and cytokeratin 7 (CK7) and cytokeratin 20 (CK20) have recently been reported to be useful to distinguish between primary and metastatic lung adenocarcinoma.
  • The aim of this study was to determine the usefulness of the staining patterns of pulmonary adenocarcinoma with antibodies to TTF-1, CK7, and CK20 in differentiating primary from metastatic pulmonary adenocarcinoma.
  • Of the 66 lung adenocarcinoma specimens that were enrolled in our study, there were 40 primary lung adenocarcinomas, 12 metastatic adenocarcinomas from breast, 13 metastatic adenocarcinomas from colon, and 1 metastatic adenocarcinoma from stomach.
  • We found that 73% of primary lung adenocarcinomas expressed TTF-1, whereas all nonpulmonary adenocarcinomas lacked TTF-1 staining.
  • In contrast, CK20 expression was significantly more prevalent in adenocarcinoma that originated in the GI tract than that of pulmonary or breast origin (p < 0.001).
  • A combination of TTF-1+CK7+CK20- was highly significantly associated with primary adenocarcinoma of lung (vs GI tract, p < 0.001; vs breast, p < 0.001).
  • A combination of TTF-1-CKCK20+ was highly significantly associated with adenocarcinoma of GI origin (vs lung, p < 0.001; vs breast, p < 0.001).
  • Our study has confirmed that expression of CK7, CK20, and TTF-1 is a useful immunohistochemical marker for diagnosis of lung tumors and for differential diagnosis of primary pulmonary adenocarcinomas from extrapulmonary adenocarcinomas metastatic to the lung.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Keratins / analysis. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16570563.001).
  • [ISSN] 1607-551X
  • [Journal-full-title] The Kaohsiung journal of medical sciences
  • [ISO-abbreviation] Kaohsiung J. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China (Republic : 1949- )
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1; 68238-35-7 / Keratins
  •  go-up   go-down


16. Akerley W, Boucher KM, Bentz JS, Arbogast K, Walters T: A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer. J Thorac Oncol; 2009 Feb;4(2):214-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of erlotinib as initial treatment for patients with stage IIIB-IV non-small cell lung cancer.
  • INTRODUCTION: Erlotinib improves survival in patients with advanced non-small cell lung cancer who have been previously treated with systemic chemotherapy.
  • METHODS: Eligibility criteria included stage IIIB/IV or recurrent non-small cell lung cancer, no prior chemotherapy for systemic disease, performance status = 0 to 1, no history of brain metastases, and weight loss less than 10%.
  • Histologies were adenocarcinoma in 22 and squamous cell in six.
  • CONCLUSIONS: Despite a modest response rate, lack of enrichment for never-smokers and absence of conventional chemotherapy in many patients, the median and long-term survivals were comparable with those expected after conventional sequencing of chemotherapy.
  • Erlotinib as initial therapy was well tolerated and warrants randomized evaluation as first-line treatment for advanced lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Protein Kinase Inhibitors / therapeutic use. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / secondary. Aged. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / secondary. Erlotinib Hydrochloride. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19179899.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


17. Yasui W, Oue N, Sentani K, Sakamoto N, Motoshita J: Transcriptome dissection of gastric cancer: identification of novel diagnostic and therapeutic targets from pathology specimens. Pathol Int; 2009 Mar;59(3):121-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastric cancer is the fourth most common malignancy in the world, and mortality due to gastric cancer is second only to that from lung cancer.
  • Regenerating islet-derived family, member 4 (Reg IV) participated in 5-fluorouracil (5-FU) resistance and peritoneal metastasis, and its expression was associated with an intestinal phenotype of gastric cancer and with endocrine differentiation.
  • GW112 expression correlated with advanced tumor stage.
  • Measurement of Reg IV and GW112 levels in sera indicated a sensitivity of 57% for detection of cancer.
  • Palate, lung, and nasal epithelium carcinoma-associated protein (PLUNC) was a useful marker for gastric hepatoid adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19261089.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 76
  •  go-up   go-down


18. Taylor MD, Smith PW, Brix WK, Wick MR, Theodosakis N, Swenson BR, Kozower BD, Jones DR: Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer. Eur J Cardiothorac Surg; 2009 Apr;35(4):699-705
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both FDG-PET maximal positron emission tomography (PET) standardized uptake values (SUVmax) and selected tumor markers have been shown to correlate with stage, nodal disease, and survival in esophageal cancer.
  • METHODS: FDG-PET SUVmax was calculated in 67 patients with esophageal cancer of which 59 (88%) had adenocarcinoma.
  • Pathologic staging included stage I (n=29, 43%), stage II (n=19, 28%), stage III disease (n=18, 27%), and stage IV disease (n=1, 2%).
  • PET SUVmax correlated with T stage (p=0.001).

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Aug 16;92(16):1316-21 [10944553.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):663-9 [11505413.001]
  • [Cites] J Clin Oncol. 2003 Feb 1;21(3):428-32 [12560430.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Feb;125(2):246-53 [12579092.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 May;125(5):1121-31 [12771886.001]
  • [Cites] Eur J Surg Oncol. 2003 Dec;29(10):890-4 [14624783.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2579-83 [15330218.001]
  • [Cites] Science. 1987 Mar 20;235(4795):1492-5 [3103217.001]
  • [Cites] Annu Rev Physiol. 1992;54:911-30 [1562197.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1637-42 [8253340.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1997 May;6(5):303-5 [9149888.001]
  • [Cites] Dis Esophagus. 2005;18(3):185-9 [16045581.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1053-9 [15964705.001]
  • [Cites] Ann Thorac Surg. 2006 Mar;81(3):1076-81 [16488726.001]
  • [Cites] J Clin Pathol. 2006 Jun;59(6):631-4 [16731604.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4283-7 [16857803.001]
  • [Cites] Ann Thorac Surg. 2006 Aug;82(2):391-4; discussion 394-5 [16863735.001]
  • [Cites] Jpn J Clin Oncol. 2006 Jul;36(7):403-9 [16782729.001]
  • [Cites] Ann Surg Oncol. 2006 Aug;13(8):1054-62 [16865594.001]
  • [Cites] Ann Surg Oncol. 2007 Feb;14(2):977-91 [17122988.001]
  • [Cites] Cancer. 2007 Feb 15;109(4):658-67 [17211865.001]
  • [Cites] J Clin Oncol. 2007 Feb 20;25(6):698-707 [17308274.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Mar;133(3):738-45 [17320575.001]
  • [Cites] Br J Cancer. 2007 May 7;96(9):1377-83 [17437013.001]
  • [Cites] Lung Cancer. 2008 Feb;59(2):203-10 [17913282.001]
  • (PMID = 19136271.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] ENG
  • [Grant] United States / NHLBI NIH HHS / HL / HL007849-09; United States / NHLBI NIH HHS / HL / T32 HL007849; United States / NHLBI NIH HHS / HL / T32 HL007849-09
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Neoplasm Proteins; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS189314; NLM/ PMC2878130
  •  go-up   go-down


19. Scagliotti GV, De Marinis F, Rinaldi M, Crinò L, Gridelli C, Ricci S, Zhao YD, Liepa AM, Peterson P, Tonato M: The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial. J Thorac Oncol; 2009 Dec;4(12):1568-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
  • INTRODUCTION: Although histology has not consistently been associated with treatment outcome in advanced non-small cell lung cancer, a recent phase III trial comparing pemetrexed plus cisplatin and gemcitabine plus cisplatin (GC) demonstrated better efficacy for pemetrexed plus cisplatin in nonsquamous (adenocarcinoma and large cell carcinoma) carcinoma than in squamous cell carcinoma.
  • Herein, retrospective analysis is used to explore the potential predictive and prognostic role of non-small cell lung cancer histology in patients treated with three first-line, platinum-based regimens.
  • Using Cox multiple regression, factors for one model included treatment (PCb, GC, and VC), histology (squamous, adenocarcinoma, large cell, and other), gender, Eastern Cooperative Oncology Group performance status (0/1 and 2), stage (IIIB and IV), number of metastatic sites (< or = 1 and >1), and smoking history (yes or no).
  • Subsequent pairwise comparisons of histology groups demonstrated a survival advantage for squamous cell carcinoma over adenocarcinoma (p = 0.0021).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / mortality. Carcinoma, Large Cell / pathology. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / mortality. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Paclitaxel / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Time Factors. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / analogs & derivatives

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009911.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 5V9KLZ54CY / Vinblastine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; Q6C979R91Y / vinorelbine
  •  go-up   go-down


20. Grodzki T, Alchimowicz J, Kozak A, Kubisa B, Pieróg J, Wójcik J, Bielewicz M, Witkowska D: Additional pulmonary resections after pneumonectomy: actual long-term survival and functional results. Eur J Cardiothorac Surg; 2008 Sep;34(3):493-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Additional pulmonary resections after pneumonectomy: actual long-term survival and functional results.
  • OBJECTIVE: Pulmonary resections after pneumonectomy due to metastases or metachronous non-small cell lung cancer (NSCLC) are rare because of the high potential risk of the second procedure and uncertain long-term results.
  • On the basis of our series (largest in Europe) we tried to assess the long-term survival of patients treated in stage IV NSCLC.
  • Sixteen resected tumors of the remaining lung were staged T1 (<3cm), 2 - T3 (<3cm but infiltration of the parietal pleura on an area of 2-4cm(2)).
  • The majority of patients died due to lung cancer (70%) but all the rest (30%) due to circulatory or respiratory insufficiency.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Forced Expiratory Volume. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Reoperation / methods. Retrospective Studies. Survival Analysis. Treatment Outcome. Vital Capacity

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Eur J Cardiothorac Surg. 2009 Feb;35(2):375; author reply 376 [19046892.001]
  • (PMID = 18583143.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Nakagawa T, Okumura N, Miyoshi K, Matsuoka T, Kameyama K: Prognostic factors in patients with ipsilateral pulmonary metastasis from non-small cell lung cancer. Eur J Cardiothorac Surg; 2005 Oct;28(4):635-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic factors in patients with ipsilateral pulmonary metastasis from non-small cell lung cancer.
  • OBJECTIVE: Pulmonary metastasis of non-small cell lung cancer is classified as an advanced disease stage, with limited indications for surgical treatment.
  • However, the prognosis of patients with pulmonary metastasis of non-small cell lung cancer is better than that of patients with distant metastases.
  • The purpose of the present study was to analyze and detect possible prognostic factors in surgically treated patients with ipsilateral pulmonary metastasis of non-small cell lung cancer.
  • METHODS: Among 1198 patients with non-small cell lung cancer who underwent surgery at Kurashiki Central Hospital (Okayama, Japan) from April 1982 to March 2004, a total of 48 (4.0%) patients with pathologically diagnosed ipsilateral pulmonary metastasis were retrospectively evaluated.
  • RESULTS: Among the 48 patients, 31 (64.6%) patients had metastatic nodules in the same lobe as the primary tumor (PM1) and 17 (35.4%) patients had metastatic nodules in different ipsilateral lobes (PM2).
  • There was no significant difference in survival between patients with PM1 and the other patients with pT4-stage IIIB, or between patients with ipsilateral PM2 and the other patients with stage IV.
  • CONCLUSIONS: The results of our study suggest that undergoing a complete resection, having a tumor size of 30mm or less and having no mediastinal lymph node metastases were better prognostic factors for surgically treated patients with ipsilateral pulmonary metastasis of non-small cell lung cancer.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / secondary. Lung Neoplasms / secondary
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Aged. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Retrospective Studies. Survival Analysis. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16126398.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Puppa G, Maisonneuve P, Sonzogni A, Masullo M, Chiappa A, Valerio M, Zampino MG, Franceschetti I, Capelli P, Chilosi M, Menestrina F, Viale G, Pelosi G: Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma. Br J Cancer; 2007 Apr 10;96(7):1118-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Independent prognostic value of fascin immunoreactivity in stage III-IV colonic adenocarcinoma.
  • In this study, we investigated the expression of fascin in 228 advanced colonic adenocarcinoma patients with a long follow-up.
  • Fascin correlated significantly with sex, tumour grade and stage, mucinous differentiation, number of metastatic lymph nodes, extranodal tumour extension, and the occurrence of distant metastases.
  • [MeSH-major] Adenocarcinoma / metabolism. Carrier Proteins / metabolism. Colonic Neoplasms / metabolism. Microfilament Proteins / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1993 Feb 15;71(4):1368-83 [8435813.001]
  • [Cites] J Cutan Pathol. 2002 Aug;29(7):430-8 [12139639.001]
  • [Cites] Am J Pathol. 1996 Feb;148(2):593-600 [8579121.001]
  • [Cites] In Vivo. 1996 Mar-Apr;10(2):153-60 [8744794.001]
  • [Cites] J Cell Biol. 1996 Sep;134(5):1271-81 [8794867.001]
  • [Cites] Hum Pathol. 1996 Nov;27(11):1124-34 [8912819.001]
  • [Cites] Dis Colon Rectum. 1997 Jan;40(1):15-24 [9102255.001]
  • [Cites] Mol Biol Cell. 1997 Nov;8(11):2345-63 [9362073.001]
  • [Cites] Mol Biol Cell. 1998 May;9(5):993-1006 [9571235.001]
  • [Cites] J Cell Biol. 1998 Oct 5;143(1):121-33 [9763425.001]
  • [Cites] J Biol Chem. 1999 Feb 26;274(9):5443-53 [10026156.001]
  • [Cites] CA Cancer J Clin. 2004 Nov-Dec;54(6):295-308 [15537574.001]
  • [Cites] Ann Surg. 2002 Oct;236(4):416-21; discussion 421 [12368669.001]
  • [Cites] Am J Pathol. 2003 Jan;162(1):69-80 [12507891.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):241-50 [12525515.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):537-47 [12592367.001]
  • [Cites] Eur J Cancer. 2003 Apr;39(6):718-27 [12651195.001]
  • [Cites] Lung Cancer. 2003 Nov;42(2):203-13 [14568688.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1572-82 [15117979.001]
  • [Cites] Histopathology. 1986 May;10(5):437-59 [3721406.001]
  • [Cites] J Cell Biol. 1986 Aug;103(2):631-40 [3525578.001]
  • [Cites] Cell Struct Funct. 1988 Oct;13(5):373-85 [3224379.001]
  • [Cites] Oncology. 2004;67(3-4):262-70 [15557788.001]
  • [Cites] Surg Oncol. 2004 Aug-Nov;13(2-3):93-101 [15572091.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):186-92 [15671545.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Clin Cancer Res. 2005 Apr 1;11(7):2597-605 [15814639.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Sep;37(9):1787-804 [16002322.001]
  • [Cites] Hum Pathol. 2005 Jul;36(7):741-6 [16084942.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Semin Oncol. 2005 Dec;32(6 Suppl 8):11-4 [16360006.001]
  • [Cites] Clin Colorectal Cancer. 2006 May;6(1):38-45 [16796790.001]
  • [Cites] Eur J Cardiothorac Surg. 2006 Sep;30(3):538-42 [16870459.001]
  • [Cites] J Clin Pathol. 2006 Sep;59(9):958-64 [16524962.001]
  • [Cites] BMC Cancer. 2006;6:241 [17029629.001]
  • [Cites] Hepatogastroenterology. 2003 Sep-Oct;50(53):1362-6 [14571738.001]
  • [Cites] J Histochem Cytochem. 2000 Feb;48(2):163-6 [10639482.001]
  • [Cites] Cancer. 2000 Apr 1;88(7):1739-57 [10738234.001]
  • [Cites] Br J Cancer. 2000 Oct;83(7):870-3 [10970687.001]
  • [Cites] Clin Exp Metastasis. 2000;18(1):83-8 [11206843.001]
  • [Cites] J Cell Biol. 2001 Mar 19;152(6):1169-82 [11257118.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2754-9 [11753948.001]
  • [Cites] Bioessays. 2002 Apr;24(4):350-61 [11948621.001]
  • [Cites] Am J Clin Pathol. 2002 Jul;118(1):52-9 [12109856.001]
  • [Cites] DNA Cell Biol. 1994 Aug;13(8):821-7 [8068206.001]
  • (PMID = 17375048.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carrier Proteins; 0 / Microfilament Proteins; 146808-54-0 / fascin
  • [Other-IDs] NLM/ PMC2360113
  •  go-up   go-down


23. Parente B, Queiroga H, Teixeira E, Sotto-Mayor R, Barata F, Sousa A, Melo MJ, João F, Neveda R, Cunha J, Fernandes A, Manuel M, Cardoso T, Ferreira L, Nogueira F, Duarte J, Semedo E, Brito U, Pimentel F, Barros S, Costa F, Almodôvar T, Araújo A: [Epidemiological study of lung cancer in Portugal (2000/2002)]. Rev Port Pneumol; 2007 Mar-Apr;13(2):255-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Epidemiological study of lung cancer in Portugal (2000/2002)].
  • [Transliterated title] Estudo epidemiológico do cancro do pulmão em Portugal nos anos de 2000/2002.
  • Lung cancer is the most common form of cancer death in the world.
  • 85% of lung cancer cases are attributable to smoking.
  • One study performed in Portugal for 3 years (2000/2002) by the Lung Oncology Work Committee of the Portuguese Society of Pulmonology in 22 Hospitals showed that of a total of 4396 patients with lung cancer, 81.8% were male and 18.2% were female, with a mean age of 64.49 +/- 11.28 years.
  • Histologically, 37.5% were adenocarcinoma, followed by squamous carcinoma in 30.5% of cases, and small cell lung cancer in 12.5%; neuroendocrine carcinoma presented in 1.4% of cases; non small cell lung cancer in 10.5%; mixed carcinoma in 0.7%; large cell carcinoma in 2.3%; and others/not specified in 4.6% of cases.
  • Staging (known in 4097 patients), showed 113 patients in stage IA (2.8%)and 250 patients in stage IB (6.1%); only 0.8% in stage IIA and 4.5% in stage IIB; 9.1% in stage IIIA and 29.9% in stage IIIB; 46.9% were already in stage IV by the time of diagnosis.
  • [MeSH-major] Lung Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571453.001).
  • [ISSN] 0873-2159
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] por
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


24. Abe T, Hayashi M, Tsutsui N, Ito K, Haraguchi M: [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2006 Feb;44(2):144-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer].
  • "Case 1" A 56-year-old woman who suffered from postoperative recurrent non-small cell lung cancer received gefitinib therapy.
  • "Case 2" A 46-year-old man with stage IV non-small cell lung cancer started gefitinib therapy after chemotherapy.
  • It has been reported that the central nervous system is a frequent metastatic site of non-small cell lung cancer in patients treated with gefitinib.
  • We should consider the possibility of metastatic central nervous system disease, even in patients in whom gefitinib therapy is apparently successful.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Brain Neoplasms / etiology. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Meningeal Neoplasms / etiology. Quinazolines / therapeutic use
  • [MeSH-minor] Adenocarcinoma / drug therapy. Disease Progression. Fatal Outcome. Female. Humans. Male. Middle Aged


25. Parini CL, Mathis D, Leath CA 3rd: Occult metastatic lung carcinoma presenting as locally advanced uterine carcinosarcoma on positron emission tomography/computed tomography imaging. Int J Gynecol Cancer; 2007 May-Jun;17(3):731-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Occult metastatic lung carcinoma presenting as locally advanced uterine carcinosarcoma on positron emission tomography/computed tomography imaging.
  • A 73-year-old postmenopausal female with stage IV nonsmall cell lung cancer presented after a PET/CT demonstrated focal uptake in the superior and lateral aspects of the uterus.
  • Postoperative pathologic review and immunohistochemical staining with thyroid transcription factor-1 revealed metastatic adenocarcinoma consistent with her lung primary in her uterus and adnexa.
  • Our case represents a rare occurrence in which lung cancer has metastasized to multiple female pelvic organs.
  • [MeSH-major] Carcinoma / pathology. Carcinosarcoma / radiography. Carcinosarcoma / secondary. Lung Neoplasms / pathology. Neoplasms, Unknown Primary / radiography. Uterine Neoplasms / radiography. Uterine Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17504386.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Srivastava AN, Gupta A, Srivastava S, Natu SM, Mittal B, Negi MP, Prasad R: Cisplatin combination chemotherapy induces oxidative stress in advance non small cell lung cancer patients. Asian Pac J Cancer Prev; 2010;11(2):465-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cisplatin combination chemotherapy induces oxidative stress in advance non small cell lung cancer patients.
  • BACKGROUND: This study determine oxidative stress and survival prospectively in advanced stage non small cell lung cancer (NSCLC) patients following cisplatin based combination chemotherapy.
  • MATERIALS AND METHODS: The oxidative stress levels (LPO, NO, GSH and SOD) of 144 control subjects and 203 advanced stage (IIIA/IIIB/IV) newly diagnosed NSCLC patients were assessed at pre-treatment (day '0'), and after the 3rd and 6th cycles of chemotherapy.
  • The oxidative stress was elevated more significantly (P<0.01) after the chemotherapy and was more evident in higher stage than lower stage patients.
  • The two year overall survival (%) of stage IV patients was significantly lower (P<0.05) as compared to stage III A and III B.
  • The proportional mortality was also maximal in stage IV patients (37.0%) followed by stage III B (31.7%) and III A (20.0%).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy. Oxidative Stress / drug effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. NITRIC OXIDE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20843135.001).
  • [ISSN] 2476-762X
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 31C4KY9ESH / Nitric Oxide; 6PLQ3CP4P3 / Etoposide; EC 1.15.1.1 / Superoxide Dismutase; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


27. Gras-Aygon C, Daures JP, Bessaoud F, Tretarre B, Crisap-LR: [Female lung cancer trends, staging and histology in Hérault, France]. Rev Epidemiol Sante Publique; 2009 Aug;57(4):275-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Female lung cancer trends, staging and histology in Hérault, France].
  • [Transliterated title] Tendance, stade, histologie du cancer bronchopulmonaire chez les femmes dans l'Hérault, France.
  • BACKGROUND: In France, lung cancer is the third most common cancer and the third leading cause of cancer death in women.
  • The main objective of this study is to analyse specificities of lung cancer in the female population in an administrative district in France, focusing on histology, staging and trends over time.
  • The variables of interest considered at diagnosis were stage, histology and age.
  • Lung cancer incidence is increasing in the female population (+6.4% per year) as well as lung cancer mortality (+3.5% per year).
  • This occurred faster for adenocarcinoma, young women and stages III-IV.
  • CONCLUSION: This population-based study confirmed the specific features of lung cancer in women: younger age at diagnosis, adenocarcinoma and stage at diagnosis with poor prognosis.
  • These results raise the question of possible differences to lung cancer susceptibility between males and females.
  • [MeSH-major] Lung Neoplasms / epidemiology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19596531.001).
  • [ISSN] 0398-7620
  • [Journal-full-title] Revue d'épidémiologie et de santé publique
  • [ISO-abbreviation] Rev Epidemiol Sante Publique
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


28. Gascon P, Pirker R, Del Mastro L, Durrwell L: Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study. Ann Oncol; 2010 Oct;21(10):2029-39
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study.
  • The objective of this study was to select a starting dose of CERA for the treatment of anemia in non-small-cell lung cancer (NSCLC) patients.
  • PATIENTS AND METHODS: The study was an open-label randomized phase II trial containing four treatment groups of patients with anemia and stage IIIB or IV NSCLC.
  • CONCLUSION: In this phase II study in patients with stage IIIB or IV NSCLC receiving chemotherapy, none of the four treatment arms showed an adequate increase in mean Hb level.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20335369.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Recombinant Proteins; 0 / continuous erythropoietin receptor activator; 11096-26-7 / Erythropoietin; 30IQX730WE / Polyethylene Glycols
  •  go-up   go-down


29. Ceribelli A, Pino MS, Gelibter AJ, Milella M, Cecere FL, Caterino M, Facciolo F, Mirri A, Cognetti F: Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel. Cancer; 2007 Feb 15;109(4):727-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sequential chemotherapy in nonsmall-cell lung cancer: cisplatin and gemcitabine followed by docetaxel.
  • BACKGROUND: Improving results in nonsmall-cell lung cancer (NSCLC) will require the development of new drugs and strategies to combine available agents.
  • METHODS: Patients with 1997 TNM stage IIIB (pleural effusion)/stage IV NSCLC, performance status (PS) of 0-1, and normal organ function were eligible.
  • RESULTS: Fifty-two eligible patients were enrolled (M/F, 39/13; stage IIIB/IV, 8/44; PS 0, 73%, PS 1, 27%; median age, 58 years; range, 36-73).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17238182.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


30. Levchenko EV, Moiseyenko VM, Matsko DE, Iyevleva AG, Ivantsov AO, Yargnian SM, Anisimov VV, Semionov II, Imyanitov EN: Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases. Onkologie; 2009 Nov;32(11):674-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases.
  • BACKGROUND: Non-small cell lung carcinomas (NSCLC) carrying a mutation in the epidermal growth factor receptor (EGFR) gene show unprecedented sensitivity to gefitinib or erlotinib.
  • CASE REPORTS: We present the follow-up data of 2 EGFR mutation-positive stage IV NSCLC patients who received upfront 250 mg gefitinib daily, then underwent potentially curative surgery, and resumed gefitinib therapy in the adjuvant setting.
  • Patient 1 was diagnosed with a rightsided adenocarcinoma of the upper lobe with multiple metastases to the middle lobe.
  • Patient 2 presented with adenocarcinoma of the lower lobe of the right lung and a single metastasis to the left adrenal.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / drug therapy. Lung Neoplasms / surgery. Protein Kinase Inhibitors / administration & dosage. Quinazolines / administration & dosage. Receptor, Epidermal Growth Factor / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Onkologie. 2009 Nov;32(11):627-8 [19887865.001]
  • (PMID = 19887873.001).
  • [ISSN] 1423-0240
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


31. Higashi K, Sakuma T, Ito K, Niho S, Ueda Y, Kobayashi T, Sekiguchi R, Takahashi T, Kato T, Tonami H: Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma. Eur J Nucl Med Mol Imaging; 2009 Mar;36(3):373-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined evaluation of preoperative FDG uptake on PET, ground-glass opacity area on CT, and serum CEA level: identification of both low and high risk of recurrence in patients with resected T1 lung adenocarcinoma.
  • PURPOSE: Patients with the same pathological stage of lung adenocarcinoma display marked variability in postoperative recurrence.
  • The aim of this study was to predict the postoperative prognosis in patients with small-sized pulmonary adenocarcinoma on the basis of FDG uptake on PET, the extent of ground-glass opacity (GGO) on CT, and serum carcinoembryonic antigen (CEA) levels.
  • METHODS: We evaluated 87 patients (40 men, 47 women; mean age 64 years, age range 42-84 years) with lung adenocarcinoma of 3.0 cm or smaller.
  • RESULTS: The patients were divided into the following four groups: those with the GGO pattern (group I, 13 patients), those with solid pattern and low FDG uptake (group II, 35 patients), those with solid pattern, high FDG uptake, and CEA <20 ng/ml (group III, 32 patients), and those with solid pattern, high FDG uptake, and CEA > or =20 ng/ml (group IV, 7 patients).
  • The 5-year disease-free survival rates were 100% in group I, 80.1% in group II, 43.7% in group III, and 16.7% in group IV (p<0.0001).
  • CONCLUSION: Combined evaluation of preoperative FDG uptake, GGO, and serum CEA level may enable patients with T1 lung adenocarcinoma at low risk and at high risk of postoperative recurrence to be identified.
  • [MeSH-major] Adenocarcinoma / diagnostic imaging. Lung Neoplasms / diagnostic imaging

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cardiothorac Surg. 2004 May;25(5):877-83 [15082298.001]
  • [Cites] Ann Thorac Surg. 2004 Apr;77(4):1157-61; discussion 1161-2 [15063225.001]
  • [Cites] AJR Am J Roentgenol. 2001 Dec;177(6):1417-22 [11717098.001]
  • [Cites] Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3 [7677489.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):61-8 [15013584.001]
  • [Cites] J Nucl Med. 2005 Feb;46(2):267-73 [15695786.001]
  • [Cites] Cancer. 2002 Dec 15;95(12):2546-54 [12467069.001]
  • [Cites] J Nucl Med. 2004 Apr;45(4):559-66 [15073250.001]
  • [Cites] Eur J Cardiothorac Surg. 2008 May;33(5):819-23 [18374589.001]
  • [Cites] Clin Radiol. 2008 Aug;63(8):856-63 [18625349.001]
  • [Cites] Eur J Nucl Med. 2001 Feb;28(2):155-64 [11303885.001]
  • [Cites] J Nucl Med. 2007 Feb;48(2):214-20 [17268017.001]
  • [Cites] J Thorac Cardiovasc Surg. 2007 Jun;133(6):1448-54 [17532938.001]
  • [Cites] J Thorac Cardiovasc Surg. 2008 Jan;135(1):44-9 [18179917.001]
  • [Cites] Radiology. 2001 Sep;220(3):803-9 [11526285.001]
  • [Cites] J Clin Oncol. 2005 Feb 20;23(6):1136-43 [15718309.001]
  • [Cites] Ann Thorac Surg. 2005 Mar;79(3):984-8; discussion 989 [15734419.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jul;173(1):75-9 [10397103.001]
  • [Cites] J Nucl Med. 1998 Jun;39(6):1016-20 [9627336.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3601-5 [16101187.001]
  • [Cites] J Clin Pathol. 1992 Jul;45(7):591-3 [1517458.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Jun;25(6):1102-6 [15145016.001]
  • [Cites] Lancet Oncol. 2004 Sep;5(9):531-40 [15337482.001]
  • [Cites] J Thorac Cardiovasc Surg. 1994 Oct;108(4):684-6 [7934103.001]
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1129-32 [15100107.001]
  • [Cites] Ann Oncol. 2005 Jan;16(1):75-80 [15598942.001]
  • (PMID = 18931837.001).
  • [ISSN] 1619-7089
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen; 0 / Fluorine Radioisotopes; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


32. Zhang J, Chen C, Zheng H, Chen G: [Clinicopathologic analysis of 57 cases of primary pulmonary mucinous adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Jan;31(1):66-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathologic analysis of 57 cases of primary pulmonary mucinous adenocarcinoma].
  • OBJECTIVE: To summarize the clinicopathological characteristics and prognostic factors of primary pulmonary mucinous adenocarcinoma (PPMA).
  • Of these 57 patients, 5 were in stage Ia, 20 in stage Ib, 1 in stage IIb, 11 in stage IIIa, 6 in stage IIIb and 14 in stage IV.
  • CONCLUSION: The final correct diagnosis of primary pulmonary mucinous adenocarcinoma should be made by pathology.
  • Though the treatment is not different, the prognosis of the patients with primary pulmonary mucinous adenocarcinoma is better than that of those with adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Lung Neoplasms / pathology. Pneumonectomy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19538874.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mitomycins; 5V9KLZ54CY / Vinblastine; Q20Q21Q62J / Cisplatin; MVP protocol 2
  • [Number-of-references] 7
  •  go-up   go-down


33. Bruzzi JF, Truong M, Zinner R, Erasmus JJ, Sabloff B, Munden R: Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy. J Thorac Oncol; 2006 Jun;1(5):425-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Short-term restaging of patients with non-small cell lung cancer receiving chemotherapy.
  • OBJECTIVE: To determine whether computed tomography (CT) performed within a month of receiving chemotherapy is useful in assessing response among patients with non-small cell lung cancer (NSCLC).
  • Tumor histology included adenocarcinoma (n = 30), squamous cell carcinoma (n = 17), and NSCLC otherwise unspecified (n = 10).
  • Clinical tumor, node, metastasis stage was stage II (n = 2), stage III (n = 11), and stage IV (n = 44).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409894.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


34. Nabili V, Natarajan S, Hirschovitz S, Bhuta S, Abemayor E: Collision tumor of thyroid: metastatic lung adenocarcinoma plus papillary thyroid carcinoma. Am J Otolaryngol; 2007 May-Jun;28(3):218-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of thyroid: metastatic lung adenocarcinoma plus papillary thyroid carcinoma.
  • We present a case of a collision tumor of metastatic lung adenocarcinoma and papillary thyroid carcinoma occurring in the thyroid gland of a 63-year-old woman who presented with a multinodular central neck mass.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoma, Papillary / pathology. Lung Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17499145.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Sandler A, Herbst R: Combining targeted agents: blocking the epidermal growth factor and vascular endothelial growth factor pathways. Clin Cancer Res; 2006 Jul 15;12(14 Pt 2):4421s-4425s
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Additionally, both agents have shown benefit in patients with previously treated non-small cell lung cancer (NSCLC).
  • A phase I/II study in two centers examined combined erlotinib and bevacizumab treatment in patients with nonsquamous stage IIIB/IV NSCLC with one or more prior chemotherapy.
  • A total of 40 patients were enrolled and treated in this study (34 patients at phase II dose): 21 were female, 30 had adenocarcinoma histology, 9 were never smokers, and 22 had two or more prior regimens.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Epidermal Growth Factor / antagonists & inhibitors. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use. Vascular Endothelial Growth Factor A / antagonists & inhibitors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16857821.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Quinazolines; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab; 62229-50-9 / Epidermal Growth Factor; DA87705X9K / Erlotinib Hydrochloride
  • [Number-of-references] 22
  •  go-up   go-down


36. Clément-Duchêne C, Carnin C, Guillemin F, Martinet Y: How accurate are physicians in the prediction of patient survival in advanced lung cancer? Oncologist; 2010;15(7):782-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] How accurate are physicians in the prediction of patient survival in advanced lung cancer?
  • BACKGROUND: Because most cases of non-small cell lung cancer (NSCLC) are diagnosed at an advanced stage with a poor prognosis, patient inclusion in clinical trials is critical.
  • The aim of this study was to assess the accuracy of clinicians' predictions of survival in NSCLC patients (stages IIIB, and IV) and the possible impact of patient quality of life on survival estimation.
  • RESULTS: Eighty-five patients with a mean age of 62.2 years, 81.1% male, were included (squamous cell carcinoma, 33; adenocarcinoma, 42; large cell carcinoma, 8; neuroendocrine carcinoma, 2).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Forecasting. Lung Neoplasms / mortality

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] BMJ. 2000 Feb 19;320(7233):469-72 [10678857.001]
  • [Cites] Oncologist. 2008;13 Suppl 1:37-46 [18263773.001]
  • [Cites] Clin Cancer Res. 2000 Mar;6(3):1125-34 [10741743.001]
  • [Cites] Radiother Oncol. 2000 Apr;55(1):19-25 [10788684.001]
  • [Cites] Chest. 2000 May;117(5):1247-55 [10807807.001]
  • [Cites] Eur J Cancer. 2000 Oct;36(16):2036-43 [11044639.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3768-74 [11078489.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2001;13(3):209-18 [11527298.001]
  • [Cites] Br J Cancer. 2003 Aug;89 Suppl 1:S35-49 [12915902.001]
  • [Cites] Cancer. 2004 Sep 1;101(5):1090-8 [15329920.001]
  • [Cites] Biometrics. 1977 Jun;33(2):363-74 [884196.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1802-13 [6478416.001]
  • [Cites] J Clin Oncol. 1995 May;13(5):1221-30 [7738625.001]
  • [Cites] Lung Cancer. 1995 Mar;12(1-2):67-76 [7600032.001]
  • [Cites] Cancer. 1996 Apr 1;77(7):1284-91 [8608504.001]
  • [Cites] Lung Cancer. 1996 Aug;15(1):67-77 [8865124.001]
  • [Cites] Eur Respir J. 1996 Sep;9(9):1826-30 [8880098.001]
  • [Cites] Thorax. 1996 Sep;51(9):894-902 [8984699.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Ann Biol Clin (Paris). 1999 Jan-Feb;57(1):57-68 [9920968.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):333-40 [10023700.001]
  • [Cites] Cancer. 1999 Jul 1;86(1):170-6 [10391577.001]
  • [Cites] J Clin Oncol. 2005 May 10;23(14):3175-85 [15886304.001]
  • [Cites] Rev Mal Respir. 2005 Dec;22(6 Pt 2):8S76-80 [16340840.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] J Pain Symptom Manage. 2006 Dec;32(6):560-6 [17157758.001]
  • [Cites] J Clin Oncol. 2007 Aug 1;25(22):3313-20 [17664480.001]
  • [Cites] Oncologist. 2008;13 Suppl 1:5-13 [18263769.001]
  • [Cites] Arch Intern Med. 2000 Mar 27;160(6):861-8 [10737287.001]
  • (PMID = 20558582.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC3228014
  •  go-up   go-down


37. Dujon C, Azarian R, Petitpretz P: [Long-term survivors of advanced non-small-cell lung cancer: characterisation and prognostic factors in a retrospective study]. Rev Mal Respir; 2009 Nov;26(9):952-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term survivors of advanced non-small-cell lung cancer: characterisation and prognostic factors in a retrospective study].
  • [Transliterated title] Longs survivants de cancers bronchiques non à petites cellules stades IIIB-IV.
  • INTRODUCTION: The prognosis of non-small cell lung cancer (NSCLC) is poor, especially for advanced stages IIIB-IV.
  • A small number of patients survive more than 2 years after diagnosis; they are called long term survivors (LS).
  • METHODS: A retrospective study in the respiratory department of a general hospital including all patients with a proven diagnosis of NSCLC stage IIIB and IV.
  • Two thirds of the patients were PS 0-1, 84.6% were stage IIIBw-IV.
  • Adenocarcinoma was the predominant histological type.
  • Univariate analysis revealed that long term survival was associated with a Charlson's score < or = 2, PS 0-1, a normal white blood cell count at diagnosis, adenocarcinoma histology, response (RP) to first line treatment and treatment with a tyrosine-kinase inhibitor (TKI).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / pathology. Survivors
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma / mortality. Adenocarcinoma / pathology. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Protein-Tyrosine Kinases / antagonists & inhibitors. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19953041.001).
  • [ISSN] 1776-2588
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


38. Zwitter M, Kovac V, Smrdel U, Vrankar M, Zadnik V: Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol; 2009 Sep;4(9):1148-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial.
  • PATIENTS AND METHODS: Eligible patients had non-small cell lung cancer in stage IIIB (wet) or IV, Karnofsky performance status 100 to 70 (Eastern Cooperative Oncology Group 0-2), measurable disease, were chemonaïve and fulfilled the standard criteria for chemotherapy.
  • Adenocarcinoma (53.9%) was the predominant histologic type; 92% of patients were in stage IV.
  • The two groups were balanced for prognostic factors; however, group A had fewer patients with significant weight loss and no patient with lung cancer as a second malignancy or after radiotherapy for brain metastases.
  • CONCLUSION: In the treatment of advanced non-small cell lung cancer, gemcitabine in low dose in prolonged infusion in combination with cisplatin has low toxicity and has activity comparable with gemcitabine in higher dose in standard brief infusion.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19546818.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


39. Reck M, Buchholz E, Romer KS, Krutzfeldt K, Gatzemeier U, Manegold C: Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer. Clin Lung Cancer; 2006 May;7(6):406-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.
  • BACKGROUND: Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor with activity in previously treated patients with advanced-stage non-small-cell lung cancer (NSCLC).
  • This phase II study (1839IL/0456) evaluated first-line gefitinib in patients with advanced-stage NSCLC.
  • PATIENTS AND METHODS: Eligible patients with proven inoperable stage III/IV NSCLC, no previous chemotherapy, and a performance status of 0-2 received gefitinib 250 mg per day until disease progression.
  • All responders were women and/or nonsmokers with adenocarcinoma or bronchoalveolar carcinoma.
  • CONCLUSION: Gefitinib monotherapy has some efficacy in chemotherapy-naive patients with advanced-stage or metastatic NSCLC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use


40. Kanaji N, Bandoh S: [Hand-foot syndrome associated with uracil/tegafur and docetaxel in a patient with lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2007 Jun;45(6):474-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hand-foot syndrome associated with uracil/tegafur and docetaxel in a patient with lung cancer].
  • A 30-year-old woman given a diagnosis of stage IV lung adenocarcinoma, was admitted to our hospital because of chest pain due to pleuritis carcinomatosa.
  • Since these drugs play a crucial role in lung cancer treatment, we need to pay attention to hand-foot syndrome.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lung Neoplasms / drug therapy. Taxoids / adverse effects

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17644943.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Taxoids; 1548R74NSZ / Tegafur; 15H5577CQD / docetaxel; 56HH86ZVCT / Uracil
  •  go-up   go-down


41. Price KA, Azzoli CG, Krug LM, Pietanza MC, Rizvi NA, Pao W, Kris MG, Riely GJ, Heelan RT, Arcila ME, Miller VA: Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer. J Thorac Oncol; 2010 Oct;5(10):1623-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
  • INTRODUCTION: Concurrent signal transduction inhibition with the epidermal growth factor receptor (EGFR) inhibitor gefitinib and the mammalian target-of-rapamycin inhibitor everolimus has been hypothesized to result in enhanced antitumor activity in patients with non-small cell lung cancer (NSCLC).
  • METHODS: Two cohorts of 31 patients with measurable stage IIIB/IV NSCLC were enrolled:.
  • RESULTS: Sixty-two patients were enrolled (median age: 66 years, 50% women, 98% stage IV, all current/former smokers, and 85% adenocarcinoma).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. SIROLIMUS .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Thorac Oncol. 2012 May;7(5):919-22 [22722792.001]
  • [Cites] Clin Cancer Res. 2003 Jun;9(6):2316-26 [12796401.001]
  • [Cites] Oncologist. 2003;8(4):303-6 [12897327.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] Science. 2004 Jun 4;304(5676):1497-500 [15118125.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 [15329413.001]
  • [Cites] N Engl J Med. 1987 Oct 8;317(15):929-35 [3041218.001]
  • [Cites] Oncogene. 1990 Jul;5(7):1037-43 [2197591.001]
  • [Cites] Carcinogenesis. 2004 Nov;25(11):2053-9 [15240509.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3226-35 [15833854.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1711-9 [15870831.001]
  • [Cites] PLoS Med. 2005 Jan;2(1):e17 [15696205.001]
  • [Cites] Eur J Cancer. 2005 Jul;41(11):1649-54 [15994075.001]
  • [Cites] Nature. 2005 Aug 11;436(7052):792 [16094359.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7052-8 [16103051.001]
  • [Cites] Lancet. 2005 Oct 29-Nov 4;366(9496):1527-37 [16257339.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):315-23 [16397245.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1500-8 [16452206.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):839-44 [16467097.001]
  • [Cites] Eur J Cancer. 2006 Aug;42(12):1875-80 [16806903.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2695-706 [16906227.001]
  • [Cites] Cancer. 2007 Aug 1;110(3):599-605 [17577220.001]
  • [Cites] Int J Cancer. 2008 May 15;122(10):2255-9 [18224685.001]
  • [Cites] J Clin Invest. 2008 Sep;118(9):3065-74 [18725988.001]
  • [Cites] Cancer Res. 2008 Sep 15;68(18):7409-18 [18794129.001]
  • [Cites] Cancer Biol Ther. 2008 Dec;7(12):1952-8 [18981735.001]
  • [Cites] Cancer Res. 2009 Apr 15;69(8):3256-61 [19351834.001]
  • [Cites] Biochem Pharmacol. 2009 Sep 1;78(5):460-8 [19427302.001]
  • [Cites] N Engl J Med. 2009 Sep 3;361(10):947-57 [19692680.001]
  • [Cites] Ann Oncol. 2009 Oct;20(10):1674-81 [19549709.001]
  • [Cites] Oncogene. 2003 May 8;22(18):2812-22 [12743604.001]
  • (PMID = 20871262.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA121210
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; 9HW64Q8G6G / Everolimus; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins; S65743JHBS / gefitinib; W36ZG6FT64 / Sirolimus
  • [Other-IDs] NLM/ NIHMS578877; NLM/ PMC4020424
  •  go-up   go-down


42. Ak G, Metintas M, Metintas S, Yildirim H, Erginel S, Alatas F: Lung cancer in individuals less than 50 years of age. Lung; 2007 Sep-Oct;185(5):279-286
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer in individuals less than 50 years of age.
  • The aim of this study was to compare the epidemiologic, clinical, and laboratory characteristics and survival rates of younger and older patients with lung cancer.
  • We studied 1340 patients who were histopathologically diagnosed as having lung cancer from 1990 to 2005.
  • In the younger group, exposure to occupational risk factors was a risk factor for lung cancer, while in the older group, smoking was a risk factor.
  • The incidence of adenocarcinoma and small-cell carcinoma was greater in the younger group, while squamous cell carcinoma was more common in the older group.
  • Metastasis rates were significantly different between the two age groups: 52.0% of the younger group presented with stage IV disease compared with 43.5% of the older group.
  • These data indicate that lung cancer had different etiopathogenetic characteristics in younger patients, which may have clinical implications.
  • [MeSH-major] Adenocarcinoma / epidemiology. Carcinoma, Small Cell / epidemiology. Carcinoma, Squamous Cell / epidemiology. Lung Neoplasms / epidemiology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 1999 May;115(5):1232-6 [10334132.001]
  • [Cites] Cancer. 1991 Mar 1;67(5):1436-8 [1991310.001]
  • [Cites] Am J Ind Med. 1989;15(5):565-78 [2741962.001]
  • [Cites] Chest. 2000 Feb;117(2):354-7 [10669674.001]
  • [Cites] Cancer Detect Prev. 1994;18(5):349-55 [7812981.001]
  • [Cites] Am Rev Respir Dis. 1986 Sep;134(3):466-70 [3752703.001]
  • [Cites] Chest. 1992 Dec;102(6):1723-9 [1446479.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):651-7 [9469354.001]
  • [Cites] Chest. 1993 Nov;104(5):1477-81 [8222810.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1730-3 [10223566.001]
  • [Cites] J Surg Oncol. 2001 Jul;77(3):208-12 [11455559.001]
  • [Cites] Respir Med. 1992 Nov;86(6):499-502 [1335158.001]
  • [Cites] Chest. 1997 Jun;111(6):1710-7 [9187198.001]
  • [Cites] Chest. 2001 Jul;120(1):32-6 [11451812.001]
  • [Cites] Chest. 1989 Dec;96(6):1298-301 [2555113.001]
  • [Cites] Chest. 1985 Apr;87(4):456-9 [2983952.001]
  • [Cites] Am J Public Health. 1987 Apr;77(4):425-31 [3826460.001]
  • [Cites] Respirology. 2001 Dec;6(4):293-6 [11844119.001]
  • [Cites] Lung Cancer. 2001 Aug-Sep;33(2-3):203-11 [11551415.001]
  • [Cites] J Clin Oncol. 1994 May;12(5):981-5 [8164051.001]
  • [Cites] Anticancer Res. 2006 Jul-Aug;26(4B):3175-81 [16886653.001]
  • [Cites] Lung Cancer. 2001 Jun;32(3):255-64 [11390007.001]
  • (PMID = 17705064.001).
  • [ISSN] 0341-2040
  • [Journal-full-title] Lung
  • [ISO-abbreviation] Lung
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Agarwala AK, Hanna NH: Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy. Clin Lung Cancer; 2005 May;6(6):367-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in a patient with stage IV non-small-cell lung carcinoma after bone metastasectomy.
  • Patients with bone metastases related to non-small-cell lung cancer (NSCLC) have a poor prognosis.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Carcinoma, Non-Small-Cell Lung / pathology. Femoral Neoplasms / secondary. Femoral Neoplasms / surgery. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15943898.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Ho JC, Mak JC, Ho SP, Ip MS, Tsang KW, Lam WK, Chan-Yeung M: Manganese superoxide dismutase and catalase genetic polymorphisms, activity levels, and lung cancer risk in Chinese in Hong Kong. J Thorac Oncol; 2006 Sep;1(7):648-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manganese superoxide dismutase and catalase genetic polymorphisms, activity levels, and lung cancer risk in Chinese in Hong Kong.
  • We investigated the risk of lung cancer development with respect to manganese superoxide dismutase (MnSOD) and catalase genetic polymorphisms and their association with erythrocyte antioxidant activities.
  • PATIENTS AND METHODS: This was a case-control study involving patients with confirmed lung cancer and age-matched healthy controls.
  • RESULTS: We recruited 240 patients with lung cancer (63% male, aged 55.6 +/- 11.9 years, 58% adenocarcinoma, 85% clinical stage III or IV) and 240 age-matched healthy controls.
  • The frequencies of the Val allele of MnSOD gene and the C allele of catalase gene were common (>86% and 90%, respectively), with similar distribution, in both patients with lung cancer and controls.
  • The homozygous variant genotypes of MnSOD and catalase were not associated with increased lung cancer risk.
  • The erythrocyte SOD and catalase activity was significantly lower among all patients with lung cancer as a whole compared with controls, irrespective of genotypes.
  • However, patients with adenocarcinoma and non-adenocarcinoma showed differences in SOD and catalase activity among different genotypes in comparison with controls.
  • CONCLUSION: The common Val16Ala MnSOD polymorphism and C-T substitution in the promoter region of the catalase gene do not confer increased or reduced risk of lung cancer in Chinese in Hong Kong.
  • [MeSH-major] Adenocarcinoma / genetics. Asian Continental Ancestry Group / genetics. Catalase / genetics. Genetic Predisposition to Disease / ethnology. Lung Neoplasms / genetics. Polymorphism, Genetic. Superoxide Dismutase / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409931.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 1.11.1.6 / Catalase; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


45. Osako T, Shiraishi I, Oorui H: [Video-assisted thoracic surgery for lung cancer at Kyoto City Hospital]. Kyobu Geka; 2009 Apr;62(4):271-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Video-assisted thoracic surgery for lung cancer at Kyoto City Hospital].
  • From April 1994 to April 2008, we were started on 313 cases video-assisted thoracic surgery (VATS) operations for primary lung cancer at the thoracic surgical department of Kyoto City Hospital.
  • Histopathologic diagnosis was adenocarcinoma was 74% and squamous cell carcinoma was 22%.
  • Five year survival rate were stage IA 87.8%, IB 71.8%, II 52.4%, III 47.8%, IV 33.3%.
  • Our data demonstrate thoracoscopic lobectomy for lung cancer is a safe procedure and excellent prognosis.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Lung Neoplasms / surgery. Pneumonectomy / methods. Thoracic Surgery, Video-Assisted / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19348209.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


46. Gibbons DL, Lin W, Creighton CJ, Rizvi ZH, Gregory PA, Goodall GJ, Thilaganathan N, Du L, Zhang Y, Pertsemlidis A, Kurie JM: Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev; 2009 Sep 15;23(18):2140-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic disease is a primary cause of cancer-related death, and factors governing tumor cell metastasis have not been fully elucidated.
  • Here, we address this question by using tumor cell lines derived from mice that develop metastatic lung adenocarcinoma owing to expression of mutant K-ras and p53.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 Oct 25;26(49):6979-88 [17486063.001]
  • [Cites] Nat Rev Cancer. 2007 Jun;7(6):415-28 [17508028.001]
  • [Cites] Cell Cycle. 2008 Mar 1;7(5):570-2 [18256538.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] Cell. 2008 May 16;133(4):704-15 [18485877.001]
  • [Cites] PLoS One. 2008;3(5):e2220 [18493606.001]
  • [Cites] J Biol Chem. 2008 May 30;283(22):14910-4 [18411277.001]
  • [Cites] EMBO Rep. 2008 Jun;9(6):582-9 [18483486.001]
  • [Cites] PLoS One. 2008;3(8):e2888 [18682804.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4078-85 [18757322.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7846-54 [18829540.001]
  • [Cites] RNA. 2008 Nov;14(11):2290-6 [18812437.001]
  • [Cites] RNA Biol. 2008 Jul-Sep;5(3):115-9 [19182522.001]
  • [Cites] PLoS One. 2009;4(4):e5401 [19404390.001]
  • [Cites] Genes Dev. 2009 Sep 15;23(18):2152-65 [19759263.001]
  • [Cites] Oncogene. 2007 Oct 18;26(48):6896-904 [17486075.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4174-9 [10760284.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):31-6 [11134512.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):167-71 [11175784.001]
  • [Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):785-92 [11533657.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3243-8 [11751630.001]
  • [Cites] Genes Dev. 2001 Dec 15;15(24):3249-62 [11751631.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Cancer Cell. 2003 Aug;4(2):111-20 [12957286.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • [Cites] Genes Chromosomes Cancer. 1991 May;3(3):168-88 [1651103.001]
  • [Cites] Oncogene. 1991 Aug;6(8):1353-62 [1679529.001]
  • [Cites] J Cell Biol. 1991 Dec;115(5):1383-95 [1955479.001]
  • [Cites] Cancer. 1996 Feb 15;77(4):665-74 [8616758.001]
  • [Cites] J Cell Biol. 1997 Apr 7;137(1):231-45 [9105051.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14821-6 [9843973.001]
  • [Cites] Bioinformatics. 2004 Nov 22;20(17):3246-8 [15180930.001]
  • [Cites] Cell. 2004 Dec 17;119(6):847-60 [15607980.001]
  • [Cites] Cell. 2004 Dec 17;119(6):861-72 [15607981.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] Oncogene. 2005 Mar 31;24(14):2375-85 [15674322.001]
  • [Cites] Cancer Cell. 2005 May;7(5):469-83 [15894267.001]
  • [Cites] Nature. 2005 Jun 9;435(7043):834-8 [15944708.001]
  • [Cites] Cell. 2005 Jun 17;121(6):823-35 [15960971.001]
  • [Cites] Curr Opin Cell Biol. 2005 Oct;17(5):548-58 [16098727.001]
  • [Cites] Cancer Res. 2005 Nov 15;65(22):10280-8 [16288016.001]
  • [Cites] Oncogene. 2006 Mar 30;25(14):2105-12 [16288213.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2746-51 [16477010.001]
  • [Cites] Cancer Cell. 2006 Jul;10(1):39-50 [16843264.001]
  • [Cites] Cancer Cell. 2007 Mar;11(3):259-73 [17349583.001]
  • [Cites] Nat Genet. 2007 May;39(5):582-3 [17460676.001]
  • [Cites] Genes Dev. 2008 Apr 1;22(7):894-907 [18381893.001]
  • (PMID = 19759262.001).
  • [ISSN] 1549-5477
  • [Journal-full-title] Genes & development
  • [ISO-abbreviation] Genes Dev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA117965; United States / NCI NIH HHS / CA / P50 CA70907; United States / NCI NIH HHS / CA / R01 CA129632; United States / NCI NIH HHS / CA / P30 CA125123; United States / NCI NIH HHS / CA / 5 T32 CA009666; United States / NCI NIH HHS / CA / R01 CA132608; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / T32 CA009666
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs; 0 / Mirn200 microRNA, mouse; 0 / Transforming Growth Factor beta
  • [Other-IDs] NLM/ PMC2751985
  •  go-up   go-down


47. Kai N, Ishii H, Morinag R, Sonoda H, Oka H, Amemiya Y, Iwata A, Otani S, Umeki K, Sakashita H, Kadota J: [Pulmonary adenocarcinoma with facial nerve palsy as the first sign of onset due to a metastatic temporal bone tumor]. Nihon Kokyuki Gakkai Zasshi; 2009 Apr;47(4):304-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pulmonary adenocarcinoma with facial nerve palsy as the first sign of onset due to a metastatic temporal bone tumor].
  • A computed tomographic scan of the chest showed a lung mass in the left lower lobe, which was thereafter diagnosed as adenocarcinoma.
  • An immunohistochemical examination of the tissue specimen obtained from the left temporal bone revealed evidence of metastatic adenocarcinoma from the lung.
  • No other metastatic lesions including separate site of bone were seen.
  • This is a very rare case of lung cancer with facial nerve palsy as the first sign of onset due to a metastatic temporal bone tumor.
  • [MeSH-major] Adenocarcinoma / pathology. Facial Paralysis / etiology. Lung Neoplasms / pathology. Skull Neoplasms / secondary. Temporal Bone

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19455960.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


48. Oteri A, Cattaneo MT, Filipazzi V, Ferrario S, Gambaro A, Isabella L, Tosca N, Clementi E, Radice S, Piazza E: A case of bullous dermatitis induced by erlotinib. Oncologist; 2009 Dec;14(12):1201-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, we report a case of bullous dermatitis that occurred in a 61-year-old woman 5 days after beginning therapy with erlotinib for the treatment of stage IV pulmonary adenocarcinoma with metastases at the hypophyseal level.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Erlotinib Hydrochloride. Female. Humans. Lung Neoplasms / drug therapy. Middle Aged. Protein Kinase Inhibitors / administration & dosage. Protein Kinase Inhibitors / adverse effects. Receptor, Epidermal Growth Factor / antagonists & inhibitors. Receptor, Epidermal Growth Factor / therapeutic use

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19965913.001).
  • [ISSN] 1549-490X
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


49. Liu DH, Wang XM, Zhang LJ, Dai SW, Liu LY, Liu JF, Wu SS, Yang SY, Fu S, Xiao XY, He DC: Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer. Biomed Environ Sci; 2007 Feb;20(1):33-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum amyloid A protein: a potential biomarker correlated with clinical stage of lung cancer.
  • OBJECTIVE: To identify serum diagnosis or progression biomarkers in patients with lung cancer using protein chip profiling analysis.
  • METHOD: Profiling analysis was performed on 450 sera collected from 213 patients with lung cancer, 19 with pneumonia, 16 with pulmonary tuberculosis, 65 with laryngeal carcinoma, 55 with laryngopharyngeal carcinoma patients, and 82 normal individuals.
  • RESULTS: Profiling analysis demonstrated that an 11.6 kDa protein was significantly elevated in lung cancer patients, compared with the control groups (P < 0.001).
  • The level and percentage of 11.6 kDa protein progressively increased with the clinical stages I-IV and were also higher in patients with squamous cell carcinoma than in other subtypes.
  • On the other hand, 11.6 kDa protein was also increased in 50% benign diseases of lung and 13% of other cancer controls.
  • CONCLUSION: SAA is a useful biomarker to monitor the progression of lung cancer and can directly identify some biomarkers on chip.
  • [MeSH-major] Biomarkers, Tumor / blood. Lung Neoplasms / blood. Serum Amyloid A Protein / analysis
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Small Cell / blood. Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / blood. Carcinoma, Squamous Cell / pathology. Female. Humans. Male. Middle Aged. Neoplasm Staging. Peptides / blood. Protein Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17458139.001).
  • [ISSN] 0895-3988
  • [Journal-full-title] Biomedical and environmental sciences : BES
  • [ISO-abbreviation] Biomed. Environ. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptides; 0 / Serum Amyloid A Protein
  •  go-up   go-down


50. Kaira K, Oriuchi N, Shimizu K, Tominaga H, Yanagitani N, Sunaga N, Ishizuka T, Kanai Y, Mori M, Endo K: 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer. J Nucl Med; 2009 Nov;50(11):1770-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FMT uptake seen within primary cancer on PET helps predict outcome of non-small cell lung cancer.
  • We evaluated the prognostic significance of (18)F-FMT PET in patients with non-small cell lung cancer.
  • METHODS: Ninety-eight patients (80 men and 18 women; age range, 42-82 y; median age, 69 y) with stage I-IV non-small cell lung cancer were enrolled in this study.
  • They included 57 with adenocarcinoma, 31 with squamous cell carcinoma, 5 with large cell carcinoma, and 5 with other conditions.
  • According to histologic types, (18)F-FMT and (18)F-FDG uptake were a stronger prognostic predictor in adenocarcinoma than in nonadenocarcinomatous disease.
  • Patients with a high SUV(max) for (18)F-FMT showed significantly worse disease-free survival rates than those with a low SUV(max), and multivariate analysis confirmed that a high SUV(max) for (18)F-FMT was an independent and significant factor in predicting a poor prognosis in patients with adenocarcinoma (P = 0.0191).
  • CONCLUSION: Uptake of (18)F-FMT in primary tumors was an independent prognostic factor in patients with pulmonary adenocarcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / metabolism. Fluorine Radioisotopes / chemistry. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. alpha-Methyltyrosine / chemistry. alpha-Methyltyrosine / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma / radionuclide imaging. Adult. Aged. Aged, 80 and over. Analysis of Variance. Female. Fluorodeoxyglucose F18 / metabolism. Humans. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19837768.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00464282
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 658-48-0 / alpha-Methyltyrosine
  •  go-up   go-down


51. Alam N, Gustafson KS, Ladanyi M, Zakowski MF, Kapoor A, Truskinovsky AM, Dudek AZ: Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung. Clin Lung Cancer; 2010 Sep 1;11(5):E1-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
  • Activating mutations in the epidermal growth factor receptor (EGFR) gene are extremely rare in small-cell lung cancer (SCLC).
  • Here, we present a case of an EGFR-mutant gefitinib-responsive non-small-cell lung cancer (NSCLC) of adenocarcinoma histology occurring in a never-smoker followed by subsequent diagnosis of metastatic SCLC carrying an EGFR mutation.
  • Although gefitinib therapy of the primary NSCLC resulted in disease control for over 3 years, the patient subsequently developed metastatic SCLC to the liver.
  • Epidermal growth factor receptor mutation analysis revealed that the exon 21 L858R activating mutation was present in both the original lung adenocarcinoma and the metastatic SCLC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Small Cell / genetics. Lung Neoplasms / genetics. Quinazolines / therapeutic use. Receptor, Epidermal Growth Factor / genetics
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / genetics. Aged. Female. Humans. Liver Neoplasms / secondary. Mutation

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20837450.001).
  • [ISSN] 1938-0690
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


52. Hanagiri T, Sugio K, Mizukami M, Ichiki Y, Sugaya M, Ono K, Yasuda M, Nozoe T, Takenoyama M, Yasumoto K: Postoperative prognosis in patients with non-small cell lung cancer according to the method of initial detection. J Thorac Oncol; 2007 Oct;2(10):907-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative prognosis in patients with non-small cell lung cancer according to the method of initial detection.
  • INTRODUCTION: In this study, we investigated the difference in the surgical results of non-small cell lung cancer according to the method of initial detection.
  • METHODS: We reviewed the medical records of 796 patients who underwent pulmonary resection for non-small cell lung cancer between 1994 and 2005.
  • The subjects consisted of 171 patients whose cancer was detected by a medical checkup or mass health screening (group I), 316 patients who were under evaluation for other diseases or with symptoms related to other diseases (group II), and 309 patients with lung cancer-related symptoms (group III).
  • RESULTS: Pathologic stage I lung cancer was found in 112 (65.5%), 209 (65.2%), and 110 (35.6%) patients in groups I, II, and III, respectively.
  • In comparison with stage II-IV cancer, stage I cancer was diagnosed more frequently in group I.
  • According to the histologic type, adenocarcinoma was found in 132 patients (77.2%) in group I.
  • CONCLUSION: Groups I and II had favorable prognoses, and the presence of symptoms related to lung cancer was a significantly unfavorable prognostic factor independent of all other factors.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / surgery. Female. Humans. Male. Middle Aged. Postoperative Period. Prognosis. Survival Rate


53. dos Santos VM, de Carvalho EP, de Azevedo Cortes J, Osterne EM: Case report. Unsuspected and widespread colon cancer in a young woman. Rev Med Chil; 2008 Feb;136(2):221-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver and lung metastasis and local lymph node invasion are reported in a 26-year-old Brazilian woman with an asymptomatic colon cancer.
  • She was admitted complaining of right upper quadrant pain, and the diagnostic procedures revealed an unsuspected adenocarcinoma (stage IV) in the descending colon.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / secondary. Lung Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Rev Med Chil. 2008 Apr;136(4):544
  • (PMID = 18483677.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Chile
  •  go-up   go-down


54. Luo L, Wang H, Ma H, Zou H, Li D, Zhou Y: [Analysis of 41 cases of primary hypervascular non-small cell lung cancer treated with embolization of emulsion of chemotherapeutics and iodized oil]. Zhongguo Fei Ai Za Zhi; 2010 May;13(5):540-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of 41 cases of primary hypervascular non-small cell lung cancer treated with embolization of emulsion of chemotherapeutics and iodized oil].
  • BACKGROUND AND OBJECTIVE: Transcatheter arterial chemotherapy and embolization is the main method in the treatment of lung cancer, but most of the reports do not study individually to small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), hypovascular and hypervascular lung cancer.
  • The CT scan with IV contrast demonstrates over moderate enhanced lesion which indicate hypervascular.
  • Suqamous carcinoma 21 cases, adenocarcinoma 15 cases and squamoadenocarcinoma 5 cases.
  • Stage IIIb 34 cases, stage IV 7 cases.
  • 33 cases of total survival tome over 12 months (80.48%), IIIb stage 29/34 (85.29%), IV stage 4/7 (57.14%).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / therapy. Chemoembolization, Therapeutic. Iodized Oil / administration & dosage. Lung Neoplasms / therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20677656.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Emulsions; 8001-40-9 / Iodized Oil
  •  go-up   go-down


55. Lal DR, Clark I, Shalkow J, Downey RJ, Shorter NA, Klimstra DS, La Quaglia MP: Primary epithelial lung malignancies in the pediatric population. Pediatr Blood Cancer; 2005 Oct 15;45(5):683-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary epithelial lung malignancies in the pediatric population.
  • BACKGROUND: Primary epithelial lung malignancies are rare in childhood and adolescence.
  • PROCEDURE: A retrospective review was performed on all patients 21 years of age or younger at diagnosis, treated for primary epithelial lung malignancies at Memorial Sloan-Kettering Cancer Center between 1980 and 2001.
  • RESULTS: We identified 11 patients with primary epithelial lung malignancy.
  • Final pathologic diagnoses included adenocarcinoma (four), carcinoid tumor (three typical, one atypical), basaloid carcinoma (two), and mucoepidermoid carcinoma (one).
  • A majority of patients presented with advanced disease (two stage III, four stage IV).
  • Patients with either advanced locoregional or distant metastatic disease were treated with multimodal therapy and a majority had rapid progression of disease.
  • CONCLUSIONS: When children and adolescents present with primary epithelial lung malignancy a majority will have advanced disease and experience a delay in diagnosis.
  • The histologic types of tumors encountered are similar to lung tumors occurring in adults, although the frequency of the various types differs.
  • Similar to the adult population, the prognosis of these tumors is dependent on histology and stage.
  • Patients with carcinoid tumors seem to have the best prognosis, followed by adenocarcinoma.
  • [MeSH-major] Carcinoma / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / pathology. Adolescent. Adult. Carcinoid Tumor / diagnosis. Carcinoid Tumor / pathology. Carcinoma, Basal Cell / diagnosis. Carcinoma, Basal Cell / pathology. Child. Diagnostic Errors. Female. Humans. Male. Pneumonia / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714450.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


56. Benjamin H, Lebanony D, Rosenwald S, Cohen L, Gibori H, Barabash N, Ashkenazi K, Goren E, Meiri E, Morgenstern S, Perelman M, Barshack I, Goren Y, Edmonston TB, Chajut A, Aharonov R, Bentwich Z, Rosenfeld N, Cohen D: A diagnostic assay based on microRNA expression accurately identifies malignant pleural mesothelioma. J Mol Diagn; 2010 Nov;12(6):771-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The definitive identification of malignant pleural mesothelioma (MPM) has significant clinical implications, yet other malignancies often involve the lung pleura, confounding the diagnosis of MPM.
  • In the absence of accurate markers, MPM can be difficult to distinguish from peripheral lung adenocarcinoma and metastatic epithelial cancers.
  • Hsa-miR-193-3p was overexpressed in MPM, while hsa-miR-200c and hsa-miR-192 were overexpressed in peripheral lung adenocarcinoma and carcinomas that frequently metastasize to lung pleura.
  • The assay reached a sensitivity of 100% and a specificity of 94% in a blinded validation set of 68 samples from the lung and pleura.

  • Genetic Alliance. consumer health - Mesothelioma, malignant.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Jan;25(1):43-50 [11145250.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6315-21 [19638575.001]
  • [Cites] Am J Clin Pathol. 2001 Aug;116(2):253-62 [11488073.001]
  • [Cites] J Clin Pathol. 2001 Oct;54(10):766-70 [11577123.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1031-51 [12883236.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1409-19 [9414184.001]
  • [Cites] Nat Genet. 2005 Jul;37(7):766-70 [15965474.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2257-61 [16461460.001]
  • [Cites] Ultrastruct Pathol. 2006 Jan-Feb;30(1):3-17 [16517466.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Mar 7;103(10):3687-92 [16505370.001]
  • [Cites] Crit Rev Toxicol. 2006 Feb;36(2):165-87 [16736942.001]
  • [Cites] Nature. 2006 Jun 1;441(7093):589-94 [16688184.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5129-35 [16951230.001]
  • [Cites] Cancer Control. 2006 Oct;13(4):255-63 [17075562.001]
  • [Cites] Hum Pathol. 2007 Jan;38(1):1-16 [17056092.001]
  • [Cites] Mol Cell. 2007 Jun 8;26(5):731-43 [17540598.001]
  • [Cites] Cell. 2007 Jun 29;129(7):1401-14 [17604727.001]
  • [Cites] Genes Dev. 2008 Apr 1;22(7):894-907 [18381893.001]
  • [Cites] Nat Biotechnol. 2008 Apr;26(4):462-9 [18362881.001]
  • [Cites] Nat Cell Biol. 2008 May;10(5):593-601 [18376396.001]
  • [Cites] J Biol Chem. 2008 May 30;283(22):14910-4 [18411277.001]
  • [Cites] Curr Opin Pulm Med. 2008 Jul;14(4):303-9 [18520263.001]
  • [Cites] Arch Pathol Lab Med. 2008 Jul;132(7):1062-72 [18605762.001]
  • [Cites] Mod Pathol. 2008 Sep;21(9):1084-94 [18587319.001]
  • [Cites] PLoS One. 2008;3(9):e3148 [18773077.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):7846-54 [18829540.001]
  • [Cites] Curr Treat Options Oncol. 2008 Jun;9(2-3):147-57 [18709470.001]
  • [Cites] J Clin Oncol. 2009 Apr 20;27(12):2030-7 [19273703.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jul;48(7):615-23 [19396864.001]
  • [Cites] Arch Pathol Lab Med. 2009 Aug;133(8):1317-31 [19653732.001]
  • [Cites] Clin Cancer Res. 2010 Jan 15;16(2):610-9 [20068099.001]
  • [Cites] Am J Respir Cell Mol Biol. 2010 Mar;42(3):312-9 [19502386.001]
  • [Cites] Mod Pathol. 2010 Jun;23(6):814-23 [20348879.001]
  • [Cites] Pathol Res Pract. 2010 Aug 15;206(8):578-84 [20418022.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):375-83 [18624795.001]
  • [Cites] Ind Health. 2001 Apr;39(2):183-5 [11341549.001]
  • (PMID = 20864637.001).
  • [ISSN] 1943-7811
  • [Journal-full-title] The Journal of molecular diagnostics : JMD
  • [ISO-abbreviation] J Mol Diagn
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC2963911
  •  go-up   go-down


57. De Castro J, Lorenzo A, Morales S, Belón J, Dorta J, Lizón J, Madroñal C, Gallurt PM, Casado E, Feliu J, Barón MG, Oncopaz Cooperative Group: Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma. Cancer Chemother Pharmacol; 2005 Feb;55(2):197-202
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of a fixed dose-rate infusion of gemcitabine associated with docetaxel in advanced non-small-cell lung carcinoma.
  • PURPOSE: To evaluate the efficacy and toxicity profile of the combination of docetaxel and prolonged gemcitabine infusion in front-line chemonaive patients with advanced non-small-cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: A total of 50 chemonaive patients diagnosed with advanced NSCLC according to the AJCC/TNM classification system were included in the present study.
  • Of the 50 patients, 28 (56%) had squamous cell carcinoma, 14 adenocarcinoma (28%), and 8 (16%) large-cell carcinoma, and 40% and 60% of patients presented with stage IIIB and IV disease, respectively.
  • Of those with stage IV disease, 33% had more than one metastatic site.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy. Taxoids / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15322824.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


58. Sánchez-Ceja SG, Reyes-Maldonado E, Vázquez-Manríquez ME, López-Luna JJ, Belmont A, Gutiérrez-Castellanos S: Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma. Lung Cancer; 2006 Nov;54(2):163-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of STAT5 and Bcl-xL, and high expression of Neu and STAT3 in non-small-cell lung carcinoma.
  • Experimental evidence suggests that in lung cancer, development, progression and an increased proliferation rate can be linked to apoptosis-related factors.
  • The objective of this study is to evaluate the status of Neu, signal transducer and activator of transcription (STAT)-3, STAT5 and Bcl-xL expression in non-small-cell lung cancer.
  • We investigated the immunohistochemical expression of these proteins in 92 non-small-cell lung cancer specimens to establish their role in lung cancer pathogenesis.
  • Finally, we found correlation among histological types of lung cancer and nuclear expression of both STAT5 (P=0.005) and nuclear Bcl-xL (P=0.003).
  • Besides, nuclear expression of Bcl-xL was correlated with TNM stage IV (distant metastasis) (P=0.02).
  • These results suggest for the first time, a relevant role for STAT5 and Bcl-xL as apoptosis-regulatory proteins in the pathogenesis of lung cancer, and overexpression of both Neu and activated STAT3, could be related with the proliferation rate in lung carcinoma cells.
  • [MeSH-major] Lung Neoplasms / metabolism. Receptor, ErbB-2 / metabolism. STAT3 Transcription Factor / metabolism. STAT5 Transcription Factor / metabolism. bcl-X Protein / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Aged, 80 and over. Apoptosis. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Non-Small-Cell Lung / metabolism. Carcinoma, Non-Small-Cell Lung / pathology. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cell Proliferation. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies


59. Serrano-Olvera A, Gerson R: [Age associated survival rate in non small cell lung cancer]. Gac Med Mex; 2009 Jan-Feb;145(1):27-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Age associated survival rate in non small cell lung cancer].
  • [Transliterated title] Supervivencia en relación con la edad en cáncer pulmonar de células no pequeñas.
  • BACKGROUND: Worldwide, lung cancer is the leading cause of death due to cancer.
  • Non small cell lung cancer (NSCLC) constitutes 70% of cases.
  • Age, ECOG, comorbidity, family background, smoking, clinical stage, histology, metastatic sites, treatment and overall survival were analyzed.
  • Adenocarcinoma was the most frequent type (78.2%, 63.9% and 54.5%).
  • Stage IIIB was observed among 17.4% of patients studied, 23.1%, 23.1% and stage IV 52.2%, 44.4%, 50%, respectively.
  • Median overall survival in stages I and II was 21 months, 18 months in stage IIIA (p > 0.05).
  • Stages IIIB-IV the median overall survival was 11, 8.5 and 4 months respectively (p= 0.034).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / mortality. Lung Neoplasms / mortality


60. Buddula A: A case report of metastatic adenocarcinoma of the gingiva. J Indian Soc Periodontol; 2009 Jan;13(1):55-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of metastatic adenocarcinoma of the gingiva.
  • Scant literature is available reporting enlargement of gingiva due the metastasis of adenocarcinoma from lung.
  • The case report presents a unique case of an adenocarcinoma in the lung metastasizing to the buccal and lingual interdental papillae of teeth numbering 34 and 35.
  • A 72-year-old female was referred to the Mayo Clinic with a recent diagnosis of metastatic stage IV adenocarcinoma of the left lung presented with an abnormal mass located on the left posterior buccal keratinized tissue adjacent to teeth numbering 34-35.
  • The tumor cells were positive for CK7 and TTF-1, and weakly positive for p63 suggesting a diagnosis of adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br Dent J. 1949 Mar 4;86(5):109-11 [18113569.001]
  • [Cites] Cancer. 1950 Jan;3(1):74-85 [15405683.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1965 Sep;20:350-62 [14342927.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Jul;19(7):831-5 [15209637.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1961 Aug;14:897-905 [13691275.001]
  • [Cites] J Periodontol. 1976 Jun;47(6):358-60 [1064724.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1969 Dec;28(6):859-61 [5260657.001]
  • [Cites] Acta Pathol Microbiol Scand. 1963;57:361-74 [14064805.001]
  • (PMID = 20376244.001).
  • [ISSN] 0975-1580
  • [Journal-full-title] Journal of Indian Society of Periodontology
  • [ISO-abbreviation] J Indian Soc Periodontol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2846678
  • [Keywords] NOTNLM ; Adenocarcinoma / gingival enlargement / metastasis
  •  go-up   go-down


61. Yang L, Liu XY, Fang J, An TT, Wu MN: [Gefitinib in the treatment of advanced non-small cell lung cancer]. Zhonghua Zhong Liu Za Zhi; 2006 Jun;28(6):474-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Gefitinib in the treatment of advanced non-small cell lung cancer].
  • OBJECTIVE: To investigate the efficacy, time to progression, survival time and toxicity of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor Gefitinib (Iressa), a target therapy agent, in the treatment of advanced non-small cell lung cancer (NSCLC), and to analyze the factors affecting the efficacy and patients' survival.
  • Seventy-six (83.5%) of the 91 patients had stage IV disease, and 42 (46.2%) had developed metastases at least two sites.
  • The disease control rate of those who had adenocarcinoma, or received second-line chemotherapy or developed skin toxicity was significantly better than the other patients (P value = 0.04, 0.02, 0.00, respectively). (2) Median time to progress (TIP) was 5.0 months (95% CI 3.26-6.74). (3) Median following-up duration was 7.5 months (1-18.
  • Non-smoker, stable diseases, skin toxicities, and controlled metastatic diseases during the treatment of gefitinib were the favorable factors affecting the survival (P value = 0.00, 0.00, 0.00, 0.01, respectively). (4) The main toxicity of gefitinib was grade I or II skin toxicity.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use


62. Hayashi M, Sekikawa A, Saijo A, Takada W, Yamawaki I, Ohkawa S: Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma. Anticancer Res; 2005 May-Jun;25(3c):2435-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of hypertrophic osteoarthropathy by gefitinib in a case with lung adenocarcinoma.
  • Hypertrophic osteoarthropathy is an important manifestation of lung carcinoma, particularly in a non-small cell tumor, and hampers quality of life.
  • Although removal of the primary tumor usually resolves this syndrome, effective treatment in patients with advanced lung carcinoma has not been established.
  • A transbronchial lung biopsy (stage T2N3M1-IV) on a cavity lesion in the left lower lobe showed the features of adenocarcinoma, while bone scintigram revealed bilaterally symmetrical abnormal uptakes in the lower extremities, suggesting secondary hypertrophic osteoarthropathy.
  • Gefitinib, as a second-line therapy, induced disappearance of the abnormal accumulation on bone scintigraphy and decrease of the cavity in the lung and of serum growth hormone.
  • The presented case suggests that the EGFR inhibitor might be a promising option for the treatment of hypertrophic osteoarthropathy with advanced lung adenocarcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / complications. Lung Neoplasms / complications. Osteoarthropathy, Secondary Hypertrophic / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080471.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Protein Kinase Inhibitors; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


63. Spigel DR, Hainsworth JD, Barton JH, Patton JF, Zubkus JD, Simons L, Griner P, Burris HA 3rd, Greco FA: Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer. J Thorac Oncol; 2010 Jun;5(6):841-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer.
  • INTRODUCTION: Pemetrexed and gemcitabine are safe and active non-small cell lung cancer (NSCLC) therapies when administered every 3 weeks.
  • METHODS: The primary objective was to assess the overall response rate in chemotherapy-naive patients with unresectable stage III/IV NSCLC.
  • Baseline characteristics included the following: median age: 66 years (41-85 years); male/female: 65%/35%; Eastern Cooperative Oncology Group 0/1/2: 19%/67%/14%; and histology: adenocarcinoma (36%), large cell (18%), squamous (13%), and mixed or not specified (34%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20421819.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 0W860991D6 / Deoxycytidine; 5Z93L87A1R / Guanine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


64. Petrovic M, Tomic I, Plavec G, Ilic S, Ilic N, Baskic D: Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer. J BUON; 2008 Jan-Mar;13(1):93-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer.
  • PURPOSE: To determine the frequency of neuron specific enolase (NSE) tissue expression and its possible influence on survival of patients treated for advanced non small cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: We studied 158 patients with histological diagnosis of NSCLC (stage III/IV).
  • Combined chemoradiotherapy was used in stage III disease (without pleural effusion), whereas chemotherapy only was used in stage III (with pleural effusion) as well as in stage IV disease.
  • The most frequent NSE expression was seen in 6/9 (66.7%) patients with large cell carcinoma and in 23/50 (46%) with adenocarcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Phosphopyruvate Hydratase / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18404793.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


65. Ou SH, Ziogas A, Zell JA: Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung. J Thorac Oncol; 2010 Apr;5(4):420-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary signet-ring carcinoma (SRC) of the lung: a population-based epidemiologic study of 262 cases with comparison to adenocarcinoma of the lung.
  • BACKGROUND: The presence of signet-ring cell component has been described as a prominent feature of EML4-ALK positive non-small cell lung cancer.
  • We investigated the clinicopathologic features and survival outcome of primary signet-ring carcinoma (SRC) of the lung with comparison to adenocarcinoma of the lung.
  • METHODS: Retrospective population-based analysis of histologically diagnosed primary SRC of the lung in the California Cancer Registry between 1989 and 2006 with comparison with adenocarcinoma of the lung.
  • RESULTS: Two hundred sixty-two histologically diagnosed primary SRC of the lung were compared to 50,089 patients with lung adenocarcinoma.
  • Patients with primary SRC of the lung were significantly younger than patients with adenocarcinoma, with a significantly higher proportion of poorly differentiated tumor and stage IV disease.
  • There was no difference in the distribution of gender and ethnicity among patients with SRC when compared to patients with adenocarcinoma.
  • Subset analysis of patients with available smoking status revealed never smokers comprised a significantly higher proportion of patients with SRC (30.8%) when compared to patients with adenocarcinoma (11.0%; p = 0.0013).
  • Patients with SRC had decreased OS (versus adenocarcinoma; unadjusted hazard ratio = 1.507; 95% confidence interval: 1.326-1.714; p < 0.0001) and was an independent unfavorable prognostic factor by multivariate analysis (versus adenocarcinoma, hazard ratio 1.214, 95% confidence interval: 1.068-1.381; p = 0.0030).
  • CONCLUSIONS: Primary SRC of the lung is a rare subtype of adenocarcinoma, carries a worse prognosis when compared to adenocarcinoma and shares many of the recently identified clinicopathologic characteristics ascribed to EML4-ALK positive non-small cell lung cancer.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / epidemiology. Adenocarcinoma, Papillary / epidemiology. Carcinoma, Acinar Cell / epidemiology. Carcinoma, Signet Ring Cell / epidemiology. Lung Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20130484.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / PC / N01-PC-35136; United States / NCI NIH HHS / PC / N01-PC-35139; United States / NCI NIH HHS / PC / N01-PC-54404
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion
  •  go-up   go-down


66. Karacetin D, Incekara O: Gemcitabine-cisplatin given on day 1 every 3 weeks in advanced non-small cell lung cancer. J BUON; 2006 Apr-Jun;11(2):181-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine-cisplatin given on day 1 every 3 weeks in advanced non-small cell lung cancer.
  • PURPOSE: To determine the activity and toxicity of a higher dose intensity of the gemcitabine plus cisplatin combination in patients with non-small cell lung cancer (NSCLC).
  • PATIENTS AND METHODS: Between June 2001-June 2003, patients with locally advanced or metastatic NSCLC and ECOG performance status 0-2 entered prospectively the study.
  • NSCLC histological subtypes were: adenocarcinoma 3, large cell carcinoma 3, and squamous cell carcinoma 29.
  • Twenty patients had stage IIIB and 15 stage IV.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17318968.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


67. Ferté C, Besse B, Dansin E, Parent F, Buisine MP, Copin MC, Penel N, Soria JC: Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma. Ann Oncol; 2010 Jun;21(6):1385-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20501506.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Case Reports; Letter; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 3.6.5.2 / ras Proteins
  • [Number-of-references] 22
  •  go-up   go-down


68. Imai K, Ashitani J, Yanagi S, Kodama T, Kyoraku Y, Sano A, Matsumoto N, Nakazato M: [A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib]. Nihon Kokyuki Gakkai Zasshi; 2007 Jan;45(1):71-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib].
  • A 74-year-old smoking man was admitted because of lung cancer with metastatic brain tumor.
  • Examinations for lung cancer and brain tumor showed adenocarcinoma (clinical stage IV).
  • Lung tumor disappeared on chest computerized tomography in January 2004 and no recurrence has been detected as of March 2006.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / administration & dosage. Lung Neoplasms / drug therapy. Quinazolines / administration & dosage

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17313031.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; S65743JHBS / gefitinib
  •  go-up   go-down


69. Babiak A, Hetzel J, Godde F, König HH, Pietsch M, Hetzel M: Mitomycin C and Vinorelbine for second-line chemotherapy in NSCLC--a phase II trial. Br J Cancer; 2007 Apr 10;96(7):1052-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Single-agent therapy with Docetaxel or Pemetrexed is the current therapy of choice for second-line treatment in advanced non-small-cell lung cancer (NSCLC).
  • Forty-two patients (stage IIIB and IV, pretreated with platinum-based chemotherapy) received 8 mg m(-2) Mitomycin C on day 1 and 25 mg m(-2) Vinorelbine on days 1 and 8 of a 28-day cycle.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. VINORELBINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 May;18(10):2095-103 [10811675.001]
  • [Cites] Breast Cancer Res. 2005;7(6):R940-52 [16280040.001]
  • [Cites] Curr Oncol Rep. 2000 Jan;2(1):96-101 [11122830.001]
  • [Cites] Curr Treat Options Oncol. 2002 Feb;3(1):53-8 [12057087.001]
  • [Cites] Lung Cancer. 2004 Feb;43(2):183-94 [14739039.001]
  • [Cites] Oncogene. 2004 Jan 29;23(4):1000-4 [14647419.001]
  • [Cites] J Clin Oncol. 2004 May 1;22(9):1589-97 [15117980.001]
  • [Cites] Cancer Treat Rep. 1984 Nov;68(11):1325-9 [6388831.001]
  • [Cites] Chest. 1985 Mar;87(3):368-72 [2982552.001]
  • [Cites] Cancer Treat Rep. 1985 Sep;69(9):945-51 [2992785.001]
  • [Cites] Control Clin Trials. 1989 Mar;10(1):1-10 [2702835.001]
  • [Cites] J Clin Oncol. 1990 May;8(5):886-91 [2159054.001]
  • [Cites] Semin Oncol. 1991 Apr;18(2 Suppl 4):42-8 [1851577.001]
  • [Cites] Am J Clin Oncol. 1991 Oct;14(5):405-11 [1659174.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10):1866-72 [8410111.001]
  • [Cites] Tumori. 1994 Feb 28;80(1):33-6 [8191595.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):645-51 [7884425.001]
  • [Cites] BMJ. 1995 Oct 7;311(7010):899-909 [7580546.001]
  • [Cites] Oncology. 1996 Jan-Feb;53(1):16-8 [8570125.001]
  • [Cites] CA Cancer J Clin. 1998 Jan-Feb;48(1):6-29 [9449931.001]
  • [Cites] Clin Cancer Res. 2005 Oct 15;11(20):7508-15 [16243825.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2354-62 [10856094.001]
  • (PMID = 17353918.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 50SG953SK6 / Mitomycin; 5V9KLZ54CY / Vinblastine; Q6C979R91Y / vinorelbine
  • [Other-IDs] NLM/ PMC2360135
  •  go-up   go-down


70. Becerra CR, Verma UN, Tran HT, Tavana D, Williams NS, Frenkel EP: Phase I dose escalation study with irinotecan, capecitabine, epirubicin, and granulocyte colony-stimulating factor support for patients with solid malignancies. Am J Clin Oncol; 2008 Jun;31(3):219-25
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study determined the maximum-tolerated dose (MTD), toxicity, and pharmacokinetics of irinotecan (CPT-11), capecitabine, and epirubicin in patients with metastatic adenocarcinoma of lung, breast, or gastrointestinal tract.
  • METHODS: Eligibility criteria included the following: documented adenocarcinoma of the lung, breast, or gastrointestinal tract, <3 prior chemotherapy regimens, Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2, age > or =18 years, adequate organ function, and signed informed consent.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Breast Neoplasms / drug therapy. Epirubicin / administration & dosage. Gastrointestinal Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Topoisomerase II Inhibitors

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18525298.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Topoisomerase II Inhibitors; 0W860991D6 / Deoxycytidine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3Z8479ZZ5X / Epirubicin; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


71. Kiura K, Takigawa N, Segawa Y, Tabata M, Shibayama T, Gemba K, Bessho A, Fujimoto N, Takata I, Hotta K, Fujiwara K, Tokuda Y, Kuyama S, Shinkai T, Ueoka H, Tanimoto M, Okayama Lung Cancer Study Group: Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial. J Thorac Oncol; 2007 Jan;2(1):44-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Triple combination chemotherapy with cisplatin, docetaxel, and irinotecan for advanced non-small cell lung cancer: a phase I/II trial.
  • BACKGROUND: To determine the recommended dose and evaluate the response rate and toxicity of triplet chemotherapy using cisplatin, docetaxel, and irinotecan for non-small cell lung cancer (NSCLC) patients with stage IIIB or IV.
  • Most patients had performance status 1 (49/65) and stage IV disease (49/65).
  • Adenocarcinoma was the most common tumor histology (55 patients).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410009.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7673326042 / irinotecan; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


72. Cadranel J, Lavolé A, Gounant V, Wislez M: [Clinical types of thoracic cancer. Bronchiolo-alveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum]. Rev Mal Respir; 2006 Nov;23(5 Pt 3):16S158-16S163
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical types of thoracic cancer. Bronchiolo-alveolar carcinoma and adenocarcinoma with bronchioloalveolar features: a clinico-pathological spectrum].
  • [Transliterated title] Formes cliniques des cancers thoraciques. Carcinome bronchiolo-alvéolaire (CBA) et adénocarcinome pulmonaire avec composante bronchiolo-alvéolaire (ADC-CBA): un continuum anatomo-clinique.
  • Bronchioloalveolar carcinoma (BAC) is a primary pulmonary adenocarcinoma (ADC) arising in the cells of the terminal respiratory unit.
  • Although stage IIIB and IV tumours were excluded from the strict WHO definition of BAC the first international workshop on this tumour in 2004 emphasised the clinico-pathological continuum that exists between BAC as defined by WHO and ADC with BAC features (ADC-BAC).
  • The high frequency of epidermal growth factor receptor (EGFR) expression and amplification and/or mutation of its gene, as well as the finding in some cases of a major response to EGFR tyrosine-kinase inhibitors, have lead to several therapeutic trials of these drugs.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / pathology. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17268353.001).
  • [ISSN] 0761-8425
  • [Journal-full-title] Revue des maladies respiratoires
  • [ISO-abbreviation] Rev Mal Respir
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 30
  •  go-up   go-down


73. Kurt M, Onal IK, Elkiran T, Altun B, Altundag K, Gullu I: Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma. Med Oncol; 2005;22(2):203-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute tumor lysis syndrome triggered by zoledronic Acid in a patient with metastatic lung adenocarcinoma.
  • We report the case of a 52-yr-old man with metastatic lung adenocarcinoma who developed tumor lysis syndrome after administration of zoledronic acid.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Diphosphonates / adverse effects. Imidazoles / adverse effects. Lung Neoplasms / pathology. Tumor Lysis Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Jun 15;100(12):2613-21 [15197804.001]
  • [Cites] Med Oncol. 2001;18(2):149-51 [11778761.001]
  • [Cites] Mayo Clin Proc. 2002 Jul;77(7):722-8 [12108612.001]
  • [Cites] Am J Med. 1997 Nov;103(5):363-7 [9375703.001]
  • [Cites] Am J Med Sci. 2003 Jan;325(1):38-40 [12544084.001]
  • [Cites] J Korean Med Sci. 2001 Feb;16(1):115-8 [11289389.001]
  • [Cites] Am J Clin Oncol. 2000 Oct;23(5):491-3 [11039510.001]
  • [Cites] Int J Hematol. 2004 Jan;79(1):37-43 [14979476.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Mar;51(3):187-92 [12655435.001]
  • [Cites] Int J Hematol. 2003 Dec;78(5):443-9 [14704038.001]
  • [Cites] Med Pediatr Oncol. 1993;21(7):521-4 [8341221.001]
  • [Cites] Am J Clin Oncol. 1995 Feb;18(1):71-3 [7847263.001]
  • [Cites] Br J Cancer. 2000 Apr;82(8):1459-68 [10780527.001]
  • [Cites] BJU Int. 2004 Jul;94(1):164-70 [15217454.001]
  • [Cites] Semin Oncol. 2002 Dec;29(6 Suppl 21):3-11 [12584689.001]
  • [Cites] Leukemia. 2000 May;14(5):841-4 [10803515.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):474-5 [12393987.001]
  • [Cites] Br J Cancer. 2003 Jun 16;88(12 ):1971-8 [12799645.001]
  • [Cites] J Bone Miner Res. 2000 Nov;15(11):2211-21 [11092402.001]
  • (PMID = 15965285.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diphosphonates; 0 / Imidazoles; 6XC1PAD3KF / zoledronic acid
  •  go-up   go-down


74. Inamura K, Togashi Y, Okui M, Ninomiya H, Hiramatsu M, Satoh Y, Okumura S, Nakagawa K, Shimoji T, Noda T, Ishikawa Y: HOXB2 as a novel prognostic indicator for stage I lung adenocarcinomas. J Thorac Oncol; 2007 Sep;2(9):802-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HOXB2 as a novel prognostic indicator for stage I lung adenocarcinomas.
  • BACKGROUND: Outcomes of patients with lung adenocarcinomas can be predicted to some extent from the pathologic stage (p-stage).
  • Although all attempts are made to fully remove cancer lesions, still a number of p-stage I patients without metastatic disease at the time of surgery develop recurrences and die of cancer.
  • It is thus very important to identify p-stage I patients who are at risk of recurrence.
  • Using real-time reverse-transcriptase polymerase chain reaction analysis, we investigated the transcriptional levels of the top metastasis-related genes using 96 independent test lung adenocarcinoma samples and investigated their correlations with the prognosis.
  • RESULTS AND CONCLUSIONS: We document evidence that p-stage I patients with HOXB2 up-regulation have a worse prognosis than those with HOXB2 down-regulation (p = 0.0065), whereas the HOXB2 status has no prognostic significance for p-stage II-IV patients.
  • Comparing tumors and corresponding normal lung tissue, we confirmed HOXB2 up-regulated lesions to have much higher HOXB2 expression than the corresponding normal tissue.
  • [MeSH-major] Adenocarcinoma. Gene Expression Regulation, Neoplastic. Homeodomain Proteins / genetics. Lung Neoplasms. RNA, Neoplasm / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Thorac Oncol. 2008 Jan;3(1):100. Ishikawa, Yuichi [added]
  • (PMID = 17805056.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HOXB2 protein, human; 0 / Homeodomain Proteins; 0 / Nuclear Proteins; 0 / RNA, Neoplasm; 0 / Transcription Factors
  •  go-up   go-down


75. Tomoda Y, Kai T, Inata J, Miyazaki K, Murai H, Yamaoka N, Kuraoka T: [Central diabetes insipidus caused by pituitary metastasis of lung cancer]. Nihon Kokyuki Gakkai Zasshi; 2005 Dec;43(12):751-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Central diabetes insipidus caused by pituitary metastasis of lung cancer].
  • After examination, lung cancer (adenocarcinoma T1NOM1, Stage IV) and central diabitus insipidus caused by pituitary metastasis of lung cancer, were diagnosed.
  • However, his lung cancer progressed.
  • Diabitus insipidus caused by lung cancer is rare.
  • [MeSH-major] Adenocarcinoma / secondary. Diabetes Insipidus, Neurogenic / etiology. Lung Neoplasms / pathology. Pituitary Neoplasms / secondary


76. Zhong XJ, Li DT, Li XL, Mu DB, Zhang XG, Luo JY: [Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas]. Ai Zheng; 2007 Jul;26(7):785-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the characteristics in recurrence and metastasis between bronchioloalveolar carcinoma and other lung adenocarcinomas].
  • Although bronchioloalveolar carcinoma is a subtype of lung adenocarcinoma, its biological features are better than those of other lung adenocarcinomas.
  • This study was to analyze differences in metastatic activity between bronchioloalveolar carcinoma and other lung adenocarcinomas.
  • METHODS: The expression of E-Cadherin, Collagen IV, vascular endothelial growth factor receptor-2 (VEGFR-2), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) in 28 specimens of stage I bronchioloalveolar carcinoma confirmed pathologically and 40 specimens of other stage I lung adenocarcinomas were detected by immunohistochemistry.
  • RESULTS: The 5-year survival rate was significantly higher in ths patients with bronchioloalveolar carcinoma than in the patients with other lung adenocarcinomas (88.7% vs. 57.3%, P < 0.05).
  • The intrathoracic recurrence rate was significantly higher and the extrathoracic metastasis rate was significantly lower in the patients with bronchioloalveolar carcinoma than in the patients with other lung adenocarcinomas (75% vs. 33.3%, 25% vs. 66.7%, P < 0.05).
  • The positive rates of Collagen IV, E-Cadherin and TIMP-1 were significantly higher in bronchioloalveolar carcinoma than in other lung adenocarcinomas (78.6% vs. 42.5%, 78.6% vs. 40.0%, 67.5% vs. 42.9%, all P < 0.01).
  • The positive rate of VEGFR-2 was significantly higher in other lung adenocarcinomas than in bronchioloalveolar carcinoma (85.7% vs. 77.5%, P < 0.05).
  • There was no significant difference in the positive rate of MMP-9 between bronchioloalveolar carcinoma and other lung adenocarcinomas (85.0% vs. 78.6%, P = 0.494).
  • CONCLUSION: As compared with other lung adenocarcinomas, stage I bronchioloalveolar carcinoma is less aggressive in clinical behavior and likely to develop intrathoracic recurrence, with less extrathoracic metastases and better prognosis.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma, Bronchiolo-Alveolar / pathology. Collagen Type IV / metabolism. Lung Neoplasms / pathology. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17626761.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cadherins; 0 / Collagen Type IV; 0 / Tissue Inhibitor of Metalloproteinase-1; EC 2.7.10.1 / Vascular Endothelial Growth Factor Receptor-2; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


77. D'Jaen GA, Pantanowitz L, Bower M, Buskin S, Neil N, Greco EM, Cooley TP, Henry D, Stem J, Dezube BJ, Stebbing J, Aboulafia DM: Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration. Clin Lung Cancer; 2010 Nov 1;11(6):396-404
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human immunodeficiency virus-associated primary lung cancer in the era of highly active antiretroviral therapy: a multi-institutional collaboration.
  • BACKGROUND: Human immunodeficiency virus (HIV)-infected individuals are at increased risk for primary lung cancer (LC).
  • HIV-LC patients, like their SEER counterparts, most frequently presented with stage IIIB/IV cancers (77% vs. 70%), usually with adenocarcinoma (46% vs. 47%) or squamous carcinoma (35% vs. 25%) histologies.
  • The median survival for both HIV-LC patients and SEER participants with stage IIIB/IV was 9 months.
  • [MeSH-major] Antiretroviral Therapy, Highly Active / methods. HIV Infections / complications. Lung Neoplasms / epidemiology
  • [MeSH-minor] Adenocarcinoma / epidemiology. Adenocarcinoma / etiology. Adenocarcinoma / therapy. Adolescent. Adult. Age Factors. Age of Onset. Aged. Aged, 80 and over. Antineoplastic Agents / adverse effects. Antineoplastic Agents / therapeutic use. CD4 Lymphocyte Count. Carcinoma, Squamous Cell / epidemiology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / therapy. Child. Databases, Factual. Female. Humans. International Cooperation. Male. Middle Aged. Neoplasm Staging. SEER Program / statistics & numerical data. Survival. Treatment Outcome. Young Adult


78. Chen KY, Chen JH, Shih JY, Yang CH, Yu CJ, Yang PC: Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors. J Thorac Oncol; 2010 Jan;5(1):82-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
  • INTRODUCTION: Lung cancer has become a disease of elderly.
  • However, there are limited data describing the specific therapies, including epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), for octogenarians with advanced non-small cell lung cancer (NSCLC).
  • METHODS: From January 2000 to December 2006, patients with NSCLC aged 80 years or older with stage IIIB or IV disease at National Taiwan University Hospital were included.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Large Cell / therapy. Carcinoma, Non-Small-Cell Lung / therapy. Carcinoma, Squamous Cell / therapy. Lung Neoplasms / therapy. Protein Kinase Inhibitors / therapeutic use

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19884854.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; S65743JHBS / gefitinib
  •  go-up   go-down


79. Choong NW, Mauer AM, Haraf DJ, Lester E, Hoffman PC, Kozloff M, Lin S, Dancey JE, Szeto L, Grushko T, Olopade OI, Salgia R, Vokes EE: Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol; 2008 Sep;3(9):1003-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer.
  • INTRODUCTION: This Phase I trial aimed to determine the maximum-tolerated-dose of erlotinib administered with two standard chemoradiotherapy regimens for non-small cell lung cancer.
  • METHODS: Unresectable stage III non-small cell lung cancer patients were enrolled in this 2-arm dose-escalation study.
  • Arm A: erlotinib with cisplatin (50 mg/m IV days 1, 8, 29, 36), etoposide (50 mg/m IV days 1-5, 29-33) and chest radiotherapy (66 Gy, 2 Gy/d) followed by docetaxel (75 mg/m IV Q21 d) for 3 cycles.
  • PATIENT CHARACTERISTICS: performance status 0 to 24 patients, 1 to 10 patients, median age 63 years, adenocarcinoma 21% and female 14 patients.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18758303.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009566-15; United States / NCI NIH HHS / CA / P30 CA014599; United States / NCI NIH HHS / CA / P30 CA14599-32; United States / NCI NIH HHS / CA / CA009566-15; United States / NCI NIH HHS / CM / N01 CM007003; United States / NCI NIH HHS / CM / N01 CM-07003-74; United States / NCI NIH HHS / CA / T32 CA009566
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Protein Kinase Inhibitors; 0 / Quinazolines; 0 / Taxoids; 15H5577CQD / docetaxel; 6PLQ3CP4P3 / Etoposide; BG3F62OND5 / Carboplatin; DA87705X9K / Erlotinib Hydrochloride; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; Q20Q21Q62J / Cisplatin
  • [Other-IDs] NLM/ NIHMS154299; NLM/ PMC4535721
  •  go-up   go-down


80. Kaur A, Falleiro JJ, Ghosh AK, Mani NS: Pulmonary carcinosarcoma masquerading as a cryptic disseminated malignancy. Indian J Pathol Microbiol; 2009 Oct-Dec;52(4):517-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • At autopsy, it was a stage IV lung malignancy and histopathology revealed a carcinosarcoma comprising an adenocarcinoma and an osteosarcoma with metastasis to the heart, lymph nodes, and both adrenals.
  • [MeSH-major] Carcinosarcoma / diagnosis. Carcinosarcoma / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19805960.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


81. Ho C, Ross H, Davies A: Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma. Clin Lung Cancer; 2006 Nov;8(3):220-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of premetrexed in patients with selected stage IIIB/IV bronchioloalveolar carcinoma.
  • [MeSH-major] Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Antineoplastic Agents / therapeutic use. Glutamates / therapeutic use. Guanine / analogs & derivatives. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239300.001).
  • [ISSN] 1525-7304
  • [Journal-full-title] Clinical lung cancer
  • [ISO-abbreviation] Clin Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Glutamates; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine
  •  go-up   go-down


82. Yu JH, Wei Q, Qi FJ, Xu HT, Wang EH: [Significance of caveolin-1 expression in primary lung cancer]. Zhonghua Bing Li Xue Za Zhi; 2006 Nov;35(11):664-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Significance of caveolin-1 expression in primary lung cancer].
  • OBJECTIVE: To study the expression of caveolin-1 in primary lung cancer and its relationship with microvessel density and clinicopathologic parameters.
  • METHODS: Immunohistochemical study for caveolin-1 and CD34 was performed on paraffin sections of 154 cases of primary lung cancer and adjacent non-neoplastic lung parenchymal tissue, as well as 36 cases with nodal metastasis.
  • Western blot assay was also employed in tumor and non-neoplastic lung tissues of the 50 cases (25 cases of pulmonary squamous cell carcinoma and 25 cases of pulmonary adenocarcinoma) with fresh specimens available.
  • The expression rate of caveolin-1 in lung cancer was 59.1%, which was significantly lower than that in normal lung tissues (P < 0.01).
  • Western blot assay confirmed that the expression of caveolin-1 in pulmonary squamous cell carcinoma and adenocarcinoma was lower than in surrounding non-neoplastic lung tissues (P < 0.01).
  • The expression was also higher in stage III and IV than in stage I and II disease (P = 0.042).
  • CONCLUSIONS: The expression of caveolin-1 is lower in lung cancer tissues than that in non-small cell carcinoma, it is also significantly correlated with tumor stage and lymph node metastasis.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Caveolin 1 / biosynthesis. Lung Neoplasms / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Blotting, Western. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Humans. Immunohistochemistry. Lung / chemistry. Lung / metabolism. Lung / pathology. Lymphatic Metastasis. Male. Microvessels / chemistry. Microvessels / metabolism. Microvessels / pathology. Middle Aged. Neoplasm Staging. Small Cell Lung Carcinoma / metabolism. Small Cell Lung Carcinoma / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17374210.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Caveolin 1
  •  go-up   go-down


83. Chen QY, Jiang ZY, Wu LJ, Zhang BY, Lu GH, Zhou JY: [Expression of alpha-tubulin and MDR1 and their correlation with the biological features of non-small cell lung carcinoma]. Zhonghua Zhong Liu Za Zhi; 2010 Apr;32(4):278-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of alpha-tubulin and MDR1 and their correlation with the biological features of non-small cell lung carcinoma].
  • OBJECTIVE: To detect the expression of alpha-tubulin and MDR1 in human non-small cell lung carcinoma (NSCLC), and to clarify their clinical significance.
  • METHODS: Paraffin embedded tissues from 158 primary non-small lung carcinomas and 30 paracancerous lung tissues were examined for expression of alpha-tubulin and MDR1 by immunohistochemistry (SP method).
  • The relationship between alpha-tubulin and MDR1 expression and the biological features of lung carcinoma was analyzed.
  • RESULTS: The positive rate of alpha-tubulin and MDR1 expressions in the lung carcinomas was 65.2% and 51.3%, respectively.
  • There was no expression of either of them in 30 paracancerous lung tissues.
  • The positive rate of alpha-tubulin expression was gradually increased with tumor progression, significantly higher in III-IV stage cancers and in poorly differentiated carcinomas (both P < 0.01).
  • There was a distinct statistically significant difference between stage I, stage II and III, and stage IV.
  • But the positive rate of MDR1 in adenocarcinoma was significantly higher than that in squamous carcinoma and undifferentiated large cell carcinomas (P < 0.01).
  • Univariate analysis showed that the 5-year survival rate of patients with negative alpha-tubulin and MDR1 expression was 30.7% and 28.5%, respectively, significantly higher than that of patients with positive alpha-tubulin and MDR1 expression (13.5% and 11.8%, respectively) (chi(2) = 20.69 and 15.52, P < 0.01, respectively), and multivariate Cox regression analysis showed that alpha-tubulin (RR = 3.287, P = 0.006) and clinical TNM stage (RR = 1.954, P = 0.025) were significantly independent predictive factor for patients with lung cancer, MDR1 and other factors could not be used as an independent predicitive factors.
  • However, there was no significant correlation between the expression of alpha-tubulin and MDR1 in lung carcinoma(r = 0.093, P > 0.05).
  • CONCLUSION: The expression of alpha-tubulin and MDR1 may play an important role in the development and progression of human non-small cell lung carcinoma.
  • Combined detection could be considered as an important index for predicting prognosis of lung carcinoma.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. P-Glycoprotein / metabolism. Tubulin / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. P-Glycoproteins. Paraffin Embedding. Precancerous Conditions / metabolism. Precancerous Conditions / pathology. Proportional Hazards Models. Survival Rate

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20510079.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / ABCB1 protein, human; 0 / P-Glycoprotein; 0 / P-Glycoproteins; 0 / TUBA1A protein, human; 0 / Tubulin
  •  go-up   go-down


84. Mego M, Sycova-Mila Z, Martanovic P, Liskova S, Obertova J, Mardiak J: Inflammatory skin metastasis as a first sign of progression of lung cancer--a case report. Klin Onkol; 2010;23(6):449-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory skin metastasis as a first sign of progression of lung cancer--a case report.
  • ICM in lung cancer are extremely rare and often misdiagnosed.
  • PATIENTS AND METHODS: We report on a 55-year-old man with metastatic lung adenocarcinoma and bone metastases in the axial skeleton and left humerus diagnosed in August 2008.
  • RESULTS: Skin biopsy revealed skin infiltration by poorly differentiated carcinoma compatible with a primary lung tumour.
  • CONCLUSION: Metastasis of lung carcinoma could be one of the causes of inflammatory skin lesions in cancer patients and these metastases should be considered in cancer patients with persisting cutaneous lesions with signs of inflammation and no response to antibiotic therapy.
  • [MeSH-major] Adenocarcinoma / secondary. Lung Neoplasms / pathology. Skin Neoplasms / secondary

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21348413.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


85. Yakan S, Caliskan C, Makay O, Denecli AG, Korkut MA: Intussusception in adults: clinical characteristics, diagnosis and operative strategies. World J Gastroenterol; 2009 Apr 28;15(16):1985-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among enteric intussusceptions, 14 were secondary to a benign process, and in one of these, the malignant cause was secondary to metastatic lung adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Abdom Imaging. 2000 Jan-Feb;25(1):45-7 [10652920.001]
  • [Cites] Dis Colon Rectum. 2007 Nov;50(11):1941-9 [17846839.001]
  • [Cites] J Clin Gastroenterol. 2003 Jan;36(1):18-21 [12488701.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Feb;13(1):39-41 [12598757.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Aug;13(4):280-2 [12960794.001]
  • [Cites] ANZ J Surg. 2003 Dec;73(12):1044-7 [14632903.001]
  • [Cites] Surg Laparosc Endosc Percutan Tech. 2003 Dec;13(6):394-6 [14712104.001]
  • [Cites] Abdom Imaging. 2004 Jan-Feb;29(1):42-4 [15160752.001]
  • [Cites] Am J Surg. 1971 May;121(5):531-5 [5557762.001]
  • [Cites] Am J Surg. 1976 Jun;131(6):758-61 [937658.001]
  • [Cites] Gastrointest Endosc. 1986 Jun;32(3):217-8 [3721141.001]
  • [Cites] Am J Surg. 1989 Jul;158(1):25-8 [2662787.001]
  • [Cites] S Afr Med J. 1990 Mar 17;77(6):313-4 [2315816.001]
  • [Cites] Gastrointest Endosc. 1990 Sep-Oct;36(5):509-11 [2227328.001]
  • [Cites] Gastrointest Radiol. 1991 Summer;16(3):264-6 [1879648.001]
  • [Cites] Langenbecks Arch Chir. 1993;378(5):288-91 [8412437.001]
  • [Cites] J Clin Gastroenterol. 1995 Oct;21(3):257 [8648067.001]
  • [Cites] Am J Surg. 1997 Feb;173(2):88-94 [9074370.001]
  • [Cites] Ann Surg. 1997 Aug;226(2):134-8 [9296505.001]
  • [Cites] Magn Reson Imaging. 1997;15(9):1095-8 [9364957.001]
  • [Cites] Clin Radiol. 1998 Jan;53(1):53-7 [9464437.001]
  • [Cites] J Am Coll Surg. 1999 Apr;188(4):390-5 [10195723.001]
  • [Cites] Radiology. 1999 Sep;212(3):853-60 [10478257.001]
  • [Cites] Postgrad Med J. 2005 Mar;81(953):174-7 [15749793.001]
  • [Cites] J Laparoendosc Adv Surg Tech A. 2005 Apr;15(2):173-5 [15898912.001]
  • [Cites] Int J Colorectal Dis. 2006 Dec;21(8):834-9 [15951987.001]
  • [Cites] Dig Dis Sci. 2007 Mar;52(3):764-6 [17268836.001]
  • [Cites] J Gastroenterol Hepatol. 2007 Nov;22(11):1767-71 [17914948.001]
  • [Cites] J Clin Ultrasound. 2002 Jan;30(1):48-51 [11807856.001]
  • (PMID = 19399931.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2675089
  •  go-up   go-down


86. Sekine I, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T: Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease. J Thorac Oncol; 2009 Apr;4(4):518-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative chemotherapeutic efficacy in non-small cell lung cancer patients with postoperative recurrence and stage IV disease.
  • BACKGROUND: Whether chemotherapy would be equally effective in non-small cell lung cancer patients with stage IV disease (group A) and postoperative recurrence (group B) remains unclear.
  • PATIENTS AND METHODS: In a total of 642 non-small cell lung cancer patients with distant metastases treated by chemotherapy, the baseline patient characteristics, responses to chemotherapy and survival were compared between group A (n = 480) and group B (n = 162).
  • RESULTS: Adenocarcinoma was the predominant histologic type, accounting for 78% of the patients in group A and 90% of the patients in group B (p < 0.001).
  • CONCLUSION: Survival was superior in patients with postoperative recurrence than in those with stage IV disease, although the two groups showed comparable responses to chemotherapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19347981.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Moore A, Lau E, Yang C, Mackool B, Kuter DJ: Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma. Am J Clin Oncol; 2007 Jun;30(3):329-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Anticoagulants / adverse effects. Dalteparin / adverse effects. Lung Neoplasms / complications. Skin Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551316.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; S79O08V79F / Dalteparin
  •  go-up   go-down


88. Seki N, Sawada S, Nakata M, Inoue T, Nishimura R, Segawa Y, Shibakuki R, Eguchi K: Lung cancer with localized ground-glass attenuation represents early-stage adenocarcinoma in nonsmokers. J Thorac Oncol; 2008 May;3(5):483-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lung cancer with localized ground-glass attenuation represents early-stage adenocarcinoma in nonsmokers.
  • BACKGROUND: Studies of lung cancer showing localized ground-glass attenuation (GGA) on thin-section computed tomography (TSCT) have been limited to resected stage IA adenocarcinomas.
  • This study aimed to clarify the features of localized GGA cancer as a distinct clinicoradiological entity through a survey of lung cancers of all types.
  • METHODS: From 2000 through 2002, 492 patients with newly diagnosed stage I-IV lung cancer underwent TSCT at a single institution.
  • Survival rates were higher in patients with a GGA ratio > or = 50% and stage IB lung cancer than in patients with a GGA ratio < 50% and stage IA lung cancer.
  • CONCLUSION: Localized GGA cancer, with presurgical prognostic factors of tumor size and GGA ratio, represents early-stage lung adenocarcinoma in nonsmokers.
  • [MeSH-major] Adenocarcinoma / pathology. Lung Neoplasms / pathology

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18449000.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


89. Kumamoto T, Suetsugu T, Iwakawa J, Tanoue A, Kawamata Y: [A case of meningeal carcinomatosis of lung adenocarcinoma well controlled by re-treatment with gefitinib]. Gan To Kagaku Ryoho; 2009 Dec;36(13):2615-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of meningeal carcinomatosis of lung adenocarcinoma well controlled by re-treatment with gefitinib].
  • A 74-year-old-woman who had never smoked was diagnosed in 2004 with cT3N2M1, stage IV primary pulmonary adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Lung Neoplasms / pathology. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / secondary. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009465.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; 0 / Quinazolines; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; S65743JHBS / gefitinib
  •  go-up   go-down


90. Hsu C, Kuo SH, Hu FC, Cheng AL, Shih JY, Yu CJ, Lin CC, Huang TC, Yang PC, Yang CH: Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial. Lung Cancer; 2008 Dec;62(3):334-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine plus conventional-dose epirubicin versus gemcitabine plus cisplatin as first-line chemotherapy for stage IIIB/IV non-small cell lung carcinoma--a randomized phase II trial.
  • BACKGROUND: Epirubicin was effective for the treatment of non-small cell lung carcinoma (NSCLC).
  • This study compared the efficacy and safety of gemcitabine plus conventional-dose epirubicin (GE) with gemcitabine-cisplatin (GC) as first-line chemotherapy for stage IIIB/IV NSCLC and evaluated the predictive value of nuclear expression of excision repair cross-complementing group 1 (ERCC1) and topoisomerase IIalpha (TopoIIalpha) on treatment outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adult. Aged. Antigens, Neoplasm / metabolism. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / metabolism. Carcinoma, Large Cell / pathology. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / metabolism. Carcinoma, Squamous Cell / pathology. Cisplatin / administration & dosage. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Endonucleases / metabolism. Epirubicin / administration & dosage. Female. Humans. Immunoenzyme Techniques. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18450322.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0W860991D6 / Deoxycytidine; 3Z8479ZZ5X / Epirubicin; B76N6SBZ8R / gemcitabine; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


91. Wang W, Shang L, Li X, Wen F, Song W, Li J: [Efficacy of docetaxel plus carboplatin combination chemotherapy for advanced non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi; 2007 Aug 20;10(4):316-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of docetaxel plus carboplatin combination chemotherapy for advanced non-small cell lung cancer].
  • BACKGROUND: Chemotherapy is one of the important treatment methods for advanced non-small cell lung cancer (NSCLC).
  • METHODS: Sixty-four stage IIIB/IV NSCLC patients were treated with docetaxel (75 mg/m² intravenously, on day 1) and carboplatin (AUC=5 intravenously, on day 2).
  • The 1-year survial rate and MST of stage IIIB patients were 44.86% and 15 months, and 39.75% and 12 months respectively in stage IV patients (P=0.0354).
  • There was no significant difference in efficacy between squamous cell carcinoma and adenocarcinoma patients.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21122302.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


92. Khan O, Tong WP, Karlin NJ: Metastatic lung adenocarcinoma in a 20-year-old patient. Curr Oncol; 2010 Feb;17(1):56-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic lung adenocarcinoma in a 20-year-old patient.
  • Lung cancer is rare disease in patients under 25 years of age.
  • He was treated for pneumonia after a chest radiograph showed total opacification of the right lung.
  • Further imaging studies showed diffuse metastatic disease.
  • Tissue immunostaining confirmed a non-small-cell lung cancer.
  • In this paper, we hope to illustrate the unique challenges in diagnosing and treating young patients with metastatic lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 1989 Mar;47(3):391-3 [2467630.001]
  • [Cites] Chest. 2001 Jul;120(1):32-6 [11451812.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1837-41 [10760760.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] Chest. 1992 Dec;102(6):1723-9 [1446479.001]
  • [Cites] Onkologie. 2008 Jun;31(6):305-8 [18547970.001]
  • [Cites] Mayo Clin Proc. 2008 May;83(5):584-94 [18452692.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Cancer. 1999 Apr 15;85(8):1730-3 [10223566.001]
  • [Cites] Arch Pathol Lab Med. 2008 Jul;132(7):1079-103 [18605764.001]
  • (PMID = 20179804.001).
  • [ISSN] 1718-7729
  • [Journal-full-title] Current oncology (Toronto, Ont.)
  • [ISO-abbreviation] Curr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC2826778
  • [Keywords] NOTNLM ; Metastatic lung cancer / non-small-cell lung cancer / young patients
  •  go-up   go-down


93. Satouchi M, Kotani Y, Katakami N, Shimada T, Urata Y, Yoshimura S, Funada Y, Hata A, Ando M, Negoro S: Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer. J Thorac Oncol; 2010 May;5(5):696-701
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II study of two different schedules of gemcitabine and oral S-1 in chemo-naïve patients with advanced non-small cell lung cancer.
  • INTRODUCTION: This study was conducted to evaluate the efficacy and safety and to compare dosing schedules of gemcitabine combined with S-1 in chemo-naïve non-small cell lung cancer patients.
  • METHODS: Patients with chemo-naïve stage IIIB/IV non-small cell lung cancer were randomized into two treatment arms.
  • CONCLUSION: The combination of gemcitabine and S-1 was determined to be feasible and effective for advanced non-small cell lung cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Squamous Cell / drug therapy. Lung Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • Genetic Alliance. consumer health - Oral cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20147856.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


94. Cortinovis D, Bidoli P, Cullurà D, Lorusso V, Ardizzoia A, Amoroso V, Bandera M, Aitini E, Fusi A, Zilembo N, Radula D, Bajetta E: Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer? J Thorac Oncol; 2008 Apr;3(4):405-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is irinotecan plus docetaxel useful as second-line therapy in advanced non-small cell lung cancer?
  • INTRODUCTION: The ability of doublet therapy in the second-line setting in patients with platinum-refractory non-small cell lung cancer (NSCLC) has not yet been proven.
  • METHODS: From March 2003 to June 2006, 65 patients (age range, 39-71 years; 83% male) with relapsed stage III/IV NSCLC were randomly assigned to receive either I 160 mg/m(2) plus D 60 mg/m(2) on day 1 every 21 days (arm A), I 80 mg/m(2) on days 1,8 plus D 60 mg/m(2) on day 1 every 21 days (arm B), or I 60 mg/m(2) plus D 30 mg/m(2) on days 1, 8, 15, and 22 every 42 days (arm C), for a maximum of 18 weeks.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Salvage Therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Prospective Studies. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18379360.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


95. Perng RP, Yang CH, Chen YM, Chang GC, Lin MC, Hsieh RK, Chu NM, Lai RS, Su WC, Tsao CJ, Hsia TC, Chen HC, Chen CH, Huang MS, Wang JL, Ho ML, Chung CY, Yu CJ, Chang WC, Kuo HP, Yu CT, Lin ZZ, Kao WY: High efficacy of erlotinib in Taiwanese NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer; 2008 Oct;62(1):78-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Erlotinib is the first epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) which has demonstrated a survival benefit in non-small-cell lung cancer (NSCLC) patients.
  • METHODS: Patients with proven stage IIIB/IV NSCLC who had received at least one line of standard chemotherapy or radiotherapy were enrolled into this study.
  • Non-smoking (p=0.033), adenocarcinoma/BAC (p=0.0027), female (p=0.0013), aged less than 65 years (p=0.0115), stage IV (p=0.0492), patients with skin rash (p=0.0216), and a higher grade of skin rash (p=0.003) were significantly correlated with response to treatment.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Quinazolines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18423781.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Quinazolines; DA87705X9K / Erlotinib Hydrochloride
  •  go-up   go-down


96. Edelman MJ, Belani CP, Socinski MA, Ansari RH, Obasaju CK, Chen R, Monberg MJ, Treat J, Alpha Oncology Research Network: Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer. J Thorac Oncol; 2010 Jan;5(1):110-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes associated with brain metastases in a three-arm phase III trial of gemcitabine-containing regimens versus paclitaxel plus carboplatin for advanced non-small cell lung cancer.
  • BACKGROUND: Brain metastases (BMs) are a common complication of non-small cell lung cancer (NSCLC).
  • METHODS: One thousand one hundred thirty-five chemonaïve patients with stage IIIB/IV NSCLC were randomized to receive gemcitabine/carboplatin, gemcitabine/paclitaxel, or paclitaxel/carboplatin.
  • Stratification was based on presence or absence of BM, stage, and baseline weight loss.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / drug therapy. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Aged. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Follow-Up Studies. Humans. Male. Neoplasm Staging. Paclitaxel / administration & dosage. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome


97. Jain AK, Hughes RS, Sandler AB, Dowlati A, Schwartzberg LS, Dobbs T, Schlabach L, Wu J, Muldowney NJ, Choy H: A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC). J Thorac Oncol; 2009 Jun;4(6):722-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of concurrent chemoradiation with weekly docetaxel, carboplatin, and radiation therapy followed by consolidation chemotherapy with docetaxel and carboplatin for locally advanced inoperable non-small cell lung cancer (NSCLC).
  • INTRODUCTION: The current standard of care for good performance status patients with locally advanced non-small cell lung carcinoma is concurrent chemoradiation, although a clearly superior regimen has not been identified.
  • Docetaxel has been shown to possess good single-agent activity against non-small cell lung cancer (NSCLC) and radiosensitizing properties, both alone and synergistically with carboplatin.
  • METHODS: Sixty-seven patients having previously untreated stage IIIA or IIIB unresectable NSCLC were enrolled, with 61 patients evaluated for endpoints.
  • Docetaxel 20 mg/m IV infusion over 30 minutes followed by carboplatin area under the curve = 2 over 30 minutes was administered weekly during concurrent thoracic radiotherapy.
  • After 3 week rest, consolidation docetaxel 75 mg/m(2) IV infusion over 60 minutes and carboplatin area under the curve = 6 over 30 minutes was administered every 3 weeks for two cycles.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / radiotherapy. Lung Neoplasms / drug therapy. Lung Neoplasms / radiotherapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Adenocarcinoma / secondary. Aged. Aged, 80 and over. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / radiotherapy. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Combined Modality Therapy. Dose Fractionation. Female. Humans. Male. Middle Aged. Prognosis. Survival Rate. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19404213.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; BG3F62OND5 / Carboplatin
  •  go-up   go-down


98. Lin J, Zhang W, Xie B, Li L, Zhang L, Zheng J, Wang X: [Clinical investigation of IRESSA in the treatment of patients with advanced refractory non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi; 2006 Oct 20;9(5):455-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical investigation of IRESSA in the treatment of patients with advanced refractory non-small cell lung cancer].
  • BACKGROUND: Chemotherapy is a main method for patients with advanced non-small cell lung cancer (NSCLC).
  • RESULTS: Totally 33 patients enrolled in this study and all were stage IV.
  • The curative effect was correlated with the pathological type, in sequence of alveolar cell carcinoma, adenocarcinoma and squamous cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176471.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


99. Herbst J, Jenders R, McKenna R, Marchevsky A: Evidence-based criteria to help distinguish metastatic breast cancer from primary lung adenocarcinoma on thoracic frozen section. Am J Clin Pathol; 2009 Jan;131(1):122-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evidence-based criteria to help distinguish metastatic breast cancer from primary lung adenocarcinoma on thoracic frozen section.
  • The distinction between primary lung adenocarcinoma and metastatic breast carcinoma in patients with a history of breast cancer is difficult by frozen section (FS) analysis.
  • The pretest odds ratio of primary pulmonary carcinoma/metastatic breast carcinoma was 2.6.
  • The incidence of 12 histopathologic features was assessed in a "training set" composed of 20 FSs, 10 with primary lung adenocarcinoma and 10 with metastatic breast cancer.
  • A differential diagnosis model composed of significant pathologic features that favor the diagnosis of primary lung adenocarcinoma (acini, lepidic growth, nuclear pseudoinclusions, and scar) or metastatic breast carcinoma (comedonecrosis, solid nests, trabecular architecture, and cribriform growth) was identified.
  • [MeSH-major] Adenocarcinoma / diagnosis. Breast Neoplasms / pathology. Frozen Sections / methods. Lung Neoplasms / diagnosis


100. Miller AA, Wang XF, Gu L, Hoffman P, Khatri J, Dunphy F, Edelman MJ, Bolger M, Vokes EE, Green MR, Cancer and Leukemia Group B (CALGB): Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). J Thorac Oncol; 2008 Oct;3(10):1159-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303).
  • INTRODUCTION: We investigated dose-dense docetaxel and cisplatin in patients with measurable non-small cell lung cancer in a randomized phase II study without [A] or with [B] a putative chemoprotective agent, BNP7787.
  • PATIENTS AND METHODS: Chemotherapy-naive patients with stage IIIB (effusion) or IV, performance status 0 to 1, and adequate organ function were eligible.
  • Its further investigation in the curative setting in non-small cell lung cancer should be considered.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Erythropoietin / analogs & derivatives. Granulocyte Colony-Stimulating Factor / therapeutic use. Lung Neoplasms / drug therapy. Mesna / analogs & derivatives
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adenocarcinoma, Bronchiolo-Alveolar / drug therapy. Adenocarcinoma, Bronchiolo-Alveolar / secondary. Adult. Aged. Anemia / drug therapy. Brain Neoplasms / drug therapy. Brain Neoplasms / secondary. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Cisplatin / administration & dosage. Darbepoetin alfa. Dose-Response Relationship, Drug. Drug Therapy, Combination. Feasibility Studies. Female. Filgrastim. Hematinics / therapeutic use. Humans. Male. Maximum Tolerated Dose. Middle Aged. Neoplasm Staging. Neutropenia / drug therapy. Prognosis. Recombinant Proteins. Survival Rate. Taxoids / administration & dosage

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DOCETAXEL .
  • Hazardous Substances Data Bank. Filgrastim .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DARBEPOETIN ALFA .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18827613.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA03927; United States / NCI NIH HHS / CA / CA114558-02; United States / NCI NIH HHS / CA / CA21060; United States / NCI NIH HHS / CA / CA31946; United States / NCI NIH HHS / CA / CA31983; United States / NCI NIH HHS / CA / CA33601; United States / NCI NIH HHS / CA / CA35113; United States / NCI NIH HHS / CA / CA35421; United States / NCI NIH HHS / CA / CA37447; United States / NCI NIH HHS / CA / CA41287; United States / NCI NIH HHS / CA / CA45389; United States / NCI NIH HHS / CA / CA45418; United States / NCI NIH HHS / CA / CA45564; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA47559; United States / NCI NIH HHS / CA / CA47577; United States / NCI NIH HHS / CA / CA47642; United States / NCI NIH HHS / CA / CA74811; United States / NCI NIH HHS / CA / CA77298; United States / NCI NIH HHS / CA / CA77440
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hematinics; 0 / Recombinant Proteins; 0 / Taxoids; 11096-26-7 / Erythropoietin; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 15H5577CQD / docetaxel; 15UQ94PT4P / Darbepoetin alfa; 3A58010674 / pegfilgrastim; 45127-11-5 / 2,2'-dithiodiethanesulfonic acid; NR7O1405Q9 / Mesna; PVI5M0M1GW / Filgrastim; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement